National Cancer Institute



2012 Fact Book

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute

2012 Fact Book

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

The information set forth in this publication is compiled and amended annually by the budget and finance staff of the National Cancer Institute and is intended primarily for the use by members of the Institute and others involved in the administration and management of the National Cancer Program. It is available online at ***www.cancer.gov***. Questions regarding any of the information contained herein may be directed to the Office of Budget and Finance, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland, 20892

TABLE OF CONTENTS

Executive Summary

Fiscal Year 2012 Annual Report iii

Organization

Director's Biography O-1
Former Directors of the NCI O-2
National Cancer Advisory Board O-4
NCI-Frederick Advisory Committee O-8
Clinical Trials and Translational Research Advisory Committee O-10
Boards of Scientific Counselors and Advisors O-14
President's Cancer Panel O-15
Scientific Program Leaders O-15
NCI Director's Consumer Liaison Group O-16
Operational Organization Charts:
- National Cancer Institute O-17
- Office of the Director O-18
  - OD I: Office of Management O-19
  - OD II: Center for Biomedical Informatics and Information Technology O-20
  - OD II: Office of Science Planning and Assessment O-20
  - OD III: Office of Communications and Education O-21
  - OD IV: Center for Cancer Genomics O-22
  - OD V: Center to Reduce Cancer Health Disparities O-23
  - OD V: Center for Strategic and Scientific Initiatives O-23
- Center for Cancer Research O-24
- Division of Cancer Biology O-26
- Division of Cancer Epidemiology and Genetics O-27
- Division of Cancer Prevention O-28
- Division of Cancer Control and Population Sciences O-29
- Division of Cancer Treatment and Diagnosis O-30
- Division of Extramural Activities O-31

Cancer Statistics

Links to Cancer Statistics C-1

Budget Data

NCI Budget B-1
Program Structure B-2
Extramural Funds B-3
NCI Obligations by Mechanism B-4
Division Obligations by Mechanism B-5
NIH Management Fund, Service & Supply Fund and GSA Rent ... B-6
Special Sources of Funds B-7
Funding for Various Research Areas B-8

Extramural Programs

Research Project Grants:
- Number of Awards E-1
- Requested, Awarded E-2
- Awards by Activity Code E-3
- Activity Code Descriptions E-4

Cancer Centers By State E-5
Specialized Programs of Research Excellence (SPORE) E-6

National Research Service Awards – Pre and Post Doctoral Trainees E-7
Construction/Renovation Funding and Building & Facilities E-8
Grant and Contract Awards by State E-9
Grant and Contract Awards by Country E-10
Institutions Receiving More than $15,000,000 in NCI Support ... E-11

Historical Trends

Appropriations of the NCI H-1
Bypass Budget Requests H-2
Comparison of Bypass Requests and Appropriations of the NCI . H-3
Comparison of Dollars, Positions and Space H-4
Personnel Resources H-5
AIDS Funding History H-6

This publication may be viewed on the World Wide Web by pointing a browser to the Office of Budget and Finance homepage at http://obf.cancer.gov/ on the National Cancer Institute's website: www.nci.nih.gov or www.cancer.gov.

Executive Summary

Fiscal Year 2012 Annual Report

BUDGET IN REVIEW

This report provides a summary of the distribution of the Fiscal Year 2012 budget among the various National Cancer Institute (NCI) research programs and funding mechanisms, funding policies influencing grant awards, and comparisons with prior year allocations. Additional information on the NCI budget is accessible from the NCI Home Page (http://www.cancer.gov).

Summary
Funds available to the NCI in FY 2012 totaled over $5.067 billion, reflecting an increase of 0.2% and $9.2 million from the previous fiscal year.

Fiscal highlights from FY 2012 include:

- Of the total NCI budget, 42.4% of the funds were allocated for Research Project Grants (RPGs).
- The total number of RPGs funded was 5,021 (includes SBIR).
- Almost one-fourth of the RPGs awarded were new (Type 1) or competing renewal (Type 2) awards.
- 1,085 competing RPGs were funded.
- One-third of the total NCI budget supported ongoing non-competing (Type 5) RPGs.
- R01 grants were funded to the 7th percentile.
- 190 grants – totaling over $77 million – were funded as Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards.
- Intramural Research comprised about 17% of the total NCI budget in FY 2012. Of this amount, about two thirds were for Labs and Bench Research and the remaining one-third was for infrastructure and support.

NCI Dollars by Mechanism for FY 2011 and 2012
(in thousands)

	2011	2012	Change '11 to '12 Am't	%
Research Project Grants:				
Noncompeting	1,631,514	1,639,445	7,931	0.5%
Admin Supplements	23,619	19,819	-3,800	-16.1%
Competing	424,494	414,004	-10,490	-2.5%
Subtotal, RPG	2,079,627	2,073,268	-6,359	-0.3%
SBIR/STTR	84,054	77,355	-6,699	-8.0%
Total, RPG	2,163,681	2,150,624	-13,057	-0.6%
Cancer Centers	278,345	279,877	1,532	0.6%
SPOREs	121,868	113,454	-8,414	-6.9%
Other P50s/P20s	35,172	33,438	-1,734	-4.9%
Other Specialized Centers	162,652	186,020	23,368	14.4%
Total: Centers, Spec Ctrs, & SPOREs	598,037	612,789	14,752	2.5%
Research Career Program	73,615	73,164	-451	-0.6%
Cancer Education	32,590	33,372	782	2.4%
Clinical Cooperative Groups	243,880	229,842	-14,038	-5.8%
Other Grants	75,546	71,164	-4,382	-5.8%
Subtotal, Other	425,631	407,542	-18,089	-4.2%
Total, Research Grants	3,187,349	3,170,954	-16,395	-0.5%
National Research Service Awards	67,654	65,992	-1,662	-2.5%
R&D Contracts	587,035	589,715	2,680	0.5%
Intramural Research	833,670	857,841	24,171	2.9%
Research Management & Support	374,477	374,919	442	0.1%
Construction	-	-	-	0.0%
Buildings and Facilities	7,920	7,920	-	0.0%
Total, NCI	5,058,105 *	5,067,342 **	9,237	0.2%
AIDS research included above	[269,953]	[271,692]	1,739	0.6%

*Cancer Prevention and Control was elimated as a Budget Mechanism in FY09.

**EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

Percent Share of Total NCI Dollars

Summary Points

- The mechanism shares of the total budget have remained relatively stable from FY 2008 to FY 2012, taking into account the elimination of Cancer Prevention and Control as a budget mechanism in FY 2009.

Percent Share of Total NCI Dollars					
	2008	2009	2010	2011	2012
Research Project Grants	43.3%	43.0%	42.5%	42.8%	42.4%
Cancer Centers	5.7%	5.8%	5.8%	5.5%	5.5%
SPOREs	2.6%	2.6%	2.6%	2.4%	2.2%
Specialized Centers	1.6%	2.3%	2.8%	3.2%	3.7%
Other P50s/P20s	-	0.6%	0.8%	0.7%	0.7%
Clinical Cooperative Groups	3.0%	4.7%	5.0%	4.8%	4.5%
R&D Contracts	9.2%	12.3%	12.0%	11.6%	11.6%
Intramural Research	14.9%	15.7%	15.8%	16.5%	16.9%
Cancer Prevention & Control*	9.9%	0.0%	0.0%	0.0%	0.0%
Other Mechanisms	9.9%	13.0%	12.7%	12.5%	12.4%

*Cancer Prevention and Control Elimated as a Budget Mechanism in FY09.



Funding Trends

Summary Points

- The NCI budget has increased by $239.7 million – or 5.0% – since FY 2008.

Historical Funding Trends (Dollars in Millions)	2008	2009	2010	2011	2012
Total NCI	$4,827.6	$4,967.0	$5,098.1	$5,058.1	$5,067.3
Research Project Grants	2,089.9	2,134.0	2,168.1	2,163.7	2,150.6
Cancer Centers	274.5	285.6	295.9	278.3	279.9
SPOREs	123.3	131.4	133.8	121.9	113.5
Other P50s/P20s	-	28.1	38.8	35.2	33.4
Other Specialized Centers	79.3	116.4	142.7	162.7	186.0
Clinical Cooperative Groups	144.0	234.5	254.5	243.9	229.8
R&D Contracts	444.2	610.1	613.8	587.0	589.7
Intramural Research	718.4	781.4	805.3	833.7	857.8
***Cancer Prevention & Control**	471.5	-	-	-	-
Other Mechanisms	482.5	645.5	645.4	631.8	626.5

% Growth by Mechanism	2008 to 2009	2009 to 2010	2010 to 2011	2011 to 2012	2008 to 2012
Total NCI	2.9%	2.6%	-0.8%	0.2%	5.0%
Research Project Grants	2.1%	1.6%	-0.2%	-0.6%	2.9%
Cancer Centers	4.0%	3.6%	-5.9%	0.6%	2.0%
SPOREs	6.6%	1.8%	-8.9%	-6.9%	-8.0%
Other P50s/P20s	-	-	100.0%	-4.9%	100.0%
Specialized Centers	46.8%	22.6%	14.0%	14.4%	134.6%
Clinical Cooperative Groups	62.8%	8.5%	-4.2%	-5.8%	59.6%
R&D Contracts	37.3%	0.6%	-4.4%	0.5%	32.8%
Intramural Research	8.8%	3.1%	3.5%	2.9%	19.4%
***Cancer Prevention & Control**	-100.0%	-	-	-	-100.0%
Other Mechanisms	33.8%	0.0%	-2.1%	-0.8%	29.9%

*Cancer Prevention and Control Elimated as a Budget Mechanism in FY09.

Research Project Grants

Summary Points

- About half of competing dollars supported grants awarded within the established payline and RFAs and half supported grants as an exception to the payline.
- RFA funds accounted for 10.1% of FY 2012 competing dollars.
- Research Project Grant applications submitted to NCI decreased slightly.
- A total of 1,085 competing RPG's were funded.

Research Project Grants*
(Dollars in Thousands)

	2011		2012	
	No.	Amount	No.	Amount
Total funding for RPGs	5,019	$2,163,681	5,021	$2,150,624
SBIR/STTR	144	$84,054	190	$77,355
Funding for RPGs without SBIR/STTR Program	4,875	$2,079,627	4,831	$2,073,268
Continuation or noncompeting grants funded	3,769	$1,655,132	3,746	$1,659,264
Competing grants funded	1,106	$424,494	1,085	$414,004
Administrative Supplements	206	$23,619	184	$19,819
Partial assessment for DHHS Program Evaluation		$75,329		$75,329
Funds set aside within competing dollars for:				
Grants within Paylines:	588	$188,865	574	$174,255
Traditional R01	338	$138,517	352	$136,052
Program Projects (P01)	-	-	-	-
RFA Grants	68	$32,131	88	$41,677
Share of competing grant funds		7.6%		10.1%
Exception Grants	474	$217,335	482	$228,534
Share of competing grant funds		51.2%		55.2%
Competing Application Requests	8,037	$3,336,074	8,014	$3,069,520
Funding Success Rate		13.8%		13.5%
Percentile funding for R01 grants		7th		7th
Average Cost-Competing		$384		$382
Average Reduction from recommended/requested levels		-17%		-17%

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds.

Grant Funding Paylines			
RPG Mechanisms:	**2011**	**2012**	
R01 Traditional Grants	7th	7th	percentile
P01 Program Projects*	N/A	N/A	priority score
R03 Small Grants	25	25	priority score
R21 Exploratory Phase I	7th	7th	percentile
R33 Exploratory Phase II	Case by Case	Case by Case	priority score
R41/R42 STTR	20	23	priority score
R43/R44 SBIR	24	24	priority score

* Formal paylines for P01 grants are determined by the Scientific Program Leadership (SPL) Committee.



National Cancer Institute
Extramural vs. Inhouse Funding
(dollars in millions)

Extramural						
Mechanism	**2008**	**2009**	**2010**	**2011**	**2012**	**08 - 12% chg.**
Research Project Grants	$2,089.9	$2,137.0	$2,168.1	$2,163.7	$2,150.6	2.9%
Cancer Centers	274.5	285.6	295.9	278.3	279.9	2.0%
SPOREs	123.3	131.4	133.8	121.9	113.5	-8.0%
Other P50s/P20s	-	28.1	38.8	35.2	33.4	100.0%
Other Specialized Centers	79.3	116.4	142.7	162.7	186.0	134.6%
Other Research Grants	317.8	417.3	442.5	425.5	407.5	28.2%
NRSA	69.9	70.1	67.6	67.7	66.0	-5.6%
R&D Contracts	444.2	610.1	613.8	587.0	589.7	32.8%
Cancer Control Grants*	190.4	-	-	-	-	-100.0%
Cancer Control Contracts*	134.8	-	-	-	-	-100.0%
Construction	-	-	-	-	-	0.0%
Buildings & Facilities	7.9	7.9	7.9	7.9	7.9	0.0%
Total Extramural Funds	**3,732.0**	**3,803.9**	**3,911.0**	**3,849.9**	**3,834.5**	**2.7%**

Inhouse						
Mechanism	**2008**	**2009**	**2010**	**2011**	**2012**	**08 - 12% chg.**
Intramural Research	$718.4	$781.4	$805.3	$833.7	$857.8	19.4%
RMS	231.0	384.6	381.8	374.5	374.9	62.3%
Control Inhouse*	146.3	-	-	-	-	-100.0%
Total Inhouse Funds	**1,095.7**	**1,166.0**	**1,187.1**	**1,208.2**	**1,232.8**	**12.5%**
Total NCI	**4,827.7**	**4,969.9**	**5,098.1**	**5,058.1**	**5,067.3**	**5.0%**

*Cancer Prevention and Control Elimated as a Budget Mechanism in FY09.



Research Career Awards – "K" Program

Summary Points

- The Research Career Award mechanism decreased by 0.6% in FY 2012.
- The number of Research Career Awards decreased by 16 between FY 2011 and FY 2012.
- NCI funded 53 awards for the NIH Pathway to Independence program.

	(Dollars in Thousands)	2011		2012	
		No.	**Amount**	**No.**	**Amount**
K01	Temin Awards	8	$1,110	51	$6,487
K01	Minority Mentored Career Development Award	48	6,265		0
	Subtotal, K01s	56	7,375	51	6,487
K05	Research Scientist Award	25	3,741	23	3,453
K07	Preventive Oncology	88	12,257	76	10,941
K08	Clinical Investigator	91	14,129	105	16,479
K12	Institutional Clinical Oncology Research	18	12,424	18	13,398
K18	Career Enhancement Award for Stem Cell Research	1	117	1	117
K22	Transition Career Development	28	4,827	25	4,452
K23	Patient-Oriented Career	38	5,937	36	3,676
K24	Patient-Oriented Career -- Mid Career	16	2,860	17	5,143
K25	Mentored Quantitative Research Career Development Award	21	2,868	17	2,274
K30	Institutional Curriculum Awards -- Administered by NCRR	0	0	0	0
K99	NIH Pathway to Independence Awards	56	7,080	53	6,744
	Total Research Career Program	438	73,615	422	73,164


National Cancer Institute
FY 2012
% of Total Research Award Funds
K99-Pathway to Independence Awards, 9.2%
K01-Temin & Minority Mentored Career Development Awards, 8.9%
K05-Research Scientist Awards, 4.7%
K07-Preventive Oncology, 15.0%
K08-Clinical Investigator, 22.5%
K12-Institutional Clinical Oncology Research, 18.3%
K18-Career Enhancement Award for Stem Cell Research, 0.2%
K22-Transition Career Development, 6.1%
K23-Patient-Oriented Career, 5.0%
K24-Patient-Oriented Career -- Mid Career, 7.0%
K25-Mentored Quantitative Research Career Development Awards, 3.1%

Research Dollars by Various Cancers

Summary Points

- Funding for various cancers listed below may overlap
- Funding for cancers listed below do not represent the entire NCI budget
- Based on NCI Coding Methodology.

Research Dollars by Various Cancers
(Dollars in Millions)

	2008	2009	2010	2011	2012
Total NCI	$4,827.6	$4,966.9	$5,098.1	$5,058.1	$5,067.3
AIDS	258.5	265.9	272.1	270.0	271.7
Brain & Central Nervous System	153.7	151.5	156.8	172.6	177.5
Breast Cancer	572.6	599.5	631.2	625.1	602.9
Cervical Cancer	76.8	70.8	77.8	81.4	72.6
Clinical Trials	853.2	846.6	852.3	877.8	753.7
Colorectal Cancer	273.7	264.2	270.4	265.1	256.3
Head and Neck	76.1	77.1	62.7	61.8	71.1
Hodgkin's Disease	17.5	18.2	14.6	13.4	15.6
Leukemia	216.4	220.6	239.7	227.0	234.7
Liver Cancer	74.2	70.3	72.6	66.2	64.6
Lung Cancer	247.6	246.9	281.9	296.8	314.6
Melanoma	110.8	103.7	102.3	115.6	121.2
Multiple Myeloma	41.5	45.2	48.5	54.9	61.3
Non Hodgkin's Lymphoma	122.6	130.9	122.4	126.4	119.5
Ovarian Cancer	100.0	110.1	112.3	110.8	111.7
Pancreatic Cancer	87.3	89.7	97.1	99.5	105.4
Prostate Cancer	285.4	293.9	300.5	288.3	265.1
Stomach Cancer	12.4	15.4	14.5	13.4	12.1
Uterine Cancer	17.1	18.0	14.2	15.9	19.1

Director's Biography
Harold Varmus, M.D.

Harold Varmus became Director of the National Cancer Institute on July 12, 2010.

Harold Varmus, co-recipient of the Nobel Prize for studies of the genetic basis of cancer, served 10 years as President of Memorial Sloan-Kettering Cancer Center and six years as Director of the National Institutes of Health. He is a member of the U.S. National Academy of Sciences and the Institute of Medicine and is involved in several initiatives to promote science and health in developing countries. The author of over 350 scientific papers and five books, including a recent memoir titled The Art and Politics of Science, he was a co-chair of President Obama's Council of Advisors on Science and Technology, was a co-founder and Chairman of the Board of the Public Library of Science, and chaired the Scientific Board of the Gates Foundation Grand Challenges in Global Health.

Former Directors of the National Cancer Institute

John E. Niederhuber, M.D. June 2006 – September 2006 (Acting) September 2006 – July 2010	John E. Niederhuber, M.D., became Director of the National Cancer Institute (NCI), one of the National Institutes of Health, in September 2006. He joined NCI in a full-time capacity in September 2005 as Deputy Director for Translational and Clinical Sciences and within a few weeks was asked to serve as Chief Operating Officer. He officially became NCI's Acting Director in June 2006. Dr. Niederhuber has also served as the Chair of the National Cancer Advisory Board, as an external NCI advisor and grant reviewer, and as a laboratory investigator supported by NCI and the NIH.
Andrew C. von Eschenbach, M.D. January 2002 – September 2005	Andrew C. von Eschenbach, M.D., became the 12th NCI Director in January 2002. He previously directed the Genitourinary Cancer Center and the Prostate Cancer Research Program at The University of Texas M.D. Anderson Cancer Center and held the Roy M. and Phyllis Gough Huffington Clinical Research Distinguished Chair in Urologic Oncology.
Richard D. Klausner, M.D. August 1995 – September 2001	Dr. Klausner was appointed as the Director of the NCI on August 1, 1995. From 1984 until 1997 he was Chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health & Human Development.
Samuel Broder, M.D. December 1988 – March 1995	Dr. Broder joined NCI in 1972 as a Clinical Associate in the Metabolism Branch. In 1981, he became Associate Director for NCI's Clinical Oncology Program.
Vincent T. DeVita, Jr., M.D. January 1980 – June 1980 (Acting) July 1980 – August 1988	Dr. DeVita joined NCI in 1963 as a Clinical Associate in the Laboratory of Chemical Pharmacology. He served NCI as head of the Solid Tumor Service, Chief of the Medicine Branch, Director of the Division of Cancer Treatment and Clinical Director prior to his appointment as Director of NCI.
Arthur Canfield Upton, M.D. July 1977 – December 1979	Prior to his tenure as NCI Director, Dr. Upton served as Dean of the School of Basic Health Sciences at the State University of New York at Stony Brook.
Frank Joseph Rauscher, Jr., Ph.D. May 1972 – October 1976	Dr. Rauscher served as Scientific Director for Etiology, NCI, prior to his appointment as Director of NCI in 1972.
Carl Gwin Baker, M.D. November 1969 – July 1970 (Acting) July 1970 – April 1972	During his tenure with PHS, Dr. Baker served as Scientific Director for Etiology, NCI, and as Acting Director of NCI prior to his appointment as Director in July 1970.
Kenneth Milo Endicott, M.D. July 1960 – November 1969	Dr. Endicott served as Chief of the Cancer Chemotherapy National Service Center, PHS, and as Associate Director, NIH, prior to being appointed Director of NCI in July 1960.
John Roderick Heller, M.D. May 1948 – June 1960	Dr. Heller joined PHS in 1934 and became Chief of the Venereal Disease Division prior to his appointment as Director of NCI in 1948.

Former Directors of the National Cancer Institute (continued)

Leonard Andrew Scheele, M.D. July 1947 – April 1948	Dr. Scheele served in various capacities during his tenure with PHS prior to his appointment as Assistant Chief and, subsequently, Director of NCI in July 1947.
Roscoe Roy Spencer, M.D. August 1943 – July 1947	Dr. Spencer became NCI's first Assistant Chief and, subsequently, was appointed Director of the Institute in 1943.
Carl Voegtlin, Ph.D. January 1938 – July 1943	Dr. Voegtlin served as Professor of Pharmacology and Chief of the Division of Pharmacy at the Hygienic Laboratory prior to becoming the first Director of NCI in 1938.

National Cancer Advisory Board (NCAB)

Membership and Term

Chairperson

2016 Tyler E. Jacks, Ph.D.
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Cambridge, MA 02157

2012 Anthony Atala, M.D.
Wake Forest Institute for Regenerative Medicine
Department of Urology
Wake Forest University School of Medicine
Winston-Salem, NC 27157

2012 Bruce A. Chabner, M.D.
Massachusetts General Hospital Cancer Center
Massachusetts General Hospital
Boston, MA 02114

2014 Victoria L. Champion, D.N.S.
Center for Research & Scholarship
Indiana University School of Nursing
Indianapolis, IN 46202

2018 David C. Christiani, M.D., M.P.H.*
Elkan Blout Professor of Environmental Genetics
Departments of Environmental Health and Environmental and Occupational Medicine and Epidemiology
Harvard School of Public Health
Professor of Medicine
Harvard Medical School
Boston, MA 02115

2012 Donald S. Coffey, Ph.D.
Departments of Urology/Oncology/Pathology
Pharmacology and Molecular Science
Johns Hopkins University School of Medicine
Baltimore, MD 21287

2016 Marcia R. Cruz-Correa, M.D., Ph.D.
University of Puerto Rico
Basic and Translational Science Director
University of Puerto Rico
Comprehensive Cancer Center
San Juan, Puerto Rico

2016 Kevin J. Cullen, M.D.
Marlene and Stewart Greenebaum Cancer Center
University of Maryland
Professor of Medicine
University of Maryland
Baltimore, MD 21201

2018 Judy E. Garber, M.D., M.P.H.*
Director
Center for Cancer Genetics and Prevention
Dana Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA 02215

2014 William H. Goodwin, Jr.
CCA Industries, Inc.
Richmond, VA 23219

2014 Waun Ki Hong, M.D.
Department of Thoracic/Head & Neck Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, TX 77030

2018 Elizabeth M. Jaffee, M.D.*
The Dana and Albert "Cubby" Broccoli Professor of Oncology
Co-Director of the Gastrointestinal Cancers Program
Associate Director for Translational Research
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Baltimore, MD 21231

2018 Beth Y. Karlan, M.D.*
Director, Women's Cancer Program
Samuel Oschin Comprehensive Cancer Institute
Director of Gynecologic Oncology
Department of Obstetrics & Gynecology
Cedar-Sinai Medical Center
Professor, Obstetrics and Gynecology
David Geffin School of Medicine, UCLA
Los Angeles, CA 90048

2012 Mr. Robert A. Ingram
Hatteras Venture Partners
Durham, NC 27701

2012 Judith S. Kaur, M.D.
Native American Programs
Mayo Comprehensive Cancer Center
Department of Medical Oncology
Mayo Clinic
Rochester, MN 55905

National Cancer Advisory Board (NCAB)

Membership and Term

2014 Mary Vaughan Lester
University of California
San Francisco Foundation
Los Angeles, CA 99024

2014 H. Kim Lyerly, M.D.
Duke University School of Medicine
Durham, NC 27705

2012 Karen M. Meneses, Ph.D.
School of Nursing
University of Alabama at Birmingham
Birmingham, AL 35294

2016 Olufunmilayo I. Olopade, M.B.B.S., F.A.C.P.
Center for Clinical Cancer Genetics
University of Chicago
Pritzker School of Medicine
Chicago, IL 60637

2014 Jennifer A. Pietenpol, Ph.D.
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, TN 37232

2018 Mack Roach III, M.D., F.A.C.R.*
Profesor of Radiation Oncology and Urology
Chair, Department of Radiation Oncology
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA 94143

2016 Johnathan M. Samet, M.D., M.S.
Professor and Flora L. Thornton Chair
Department of Preventative Medicine
Keck School of Medicine
Director, Institute for Global Health
University of Southern California
Los Angeles, CA

2018 Charles L. Sawyer, M.D.*
Chairman
Human Onocology and Pathogenesis Program
Memorial Sloan-Kettering Cancer Center
Investigator
Howard Hughes Medical Institute
Professor of Medicine
Weill-Cornell Medical College
New York, NY 10065

2016 William R. Sellers, M.D.
Vice President/Global Head of Oncology
Novartis Institutes for BioMedical Research, Inc.
Cambridge, MA

Executive Secretary
Paulette S. Gray, Ph.D.

Committee Management Officer
Ms. Claire L. Harris

* Newly appointed member pending personnel paperwork

Ex Officio Members

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S.
Director
National Institute of Environmental Health
Sciences and The National Technology Program
National Institutes of Health
Research Triangle Park, NC

Francis S. Collins, M.D., Ph.D.
Director
National Institutes of Health
Bethesda, MD

Margaret A. Hamburg, M.D.
Commissioner
Food and Drug Administration
Silver Spring, MD

John P. Holdren, Ph.D.
Science Advisor to the President
Director
Office of Science and Technology Policy
Executive Office of the President
Washington, DC

John Howard, M.D., M.P.H., J.D., LL.M.
Director
National Institute for Occupational Safety and Health
Washington, DC

Lisa Jackson, M.S.
Administrator
Environmental Protection Agency
Washington, DC

The Honorable Dr. Michael J. Kussman
Under Secretary for Health
Veterans Health Administration
Department of Veterans Affairs
Washington, DC

Anna Palmisano, Ph.D.
Associate Director, Office of Biological and
Environmental Research
Department of Energy
Washington, DC

The Honorable Kathleen Sebelius, M.P.A.
Secretary
Department of Health and Human Services
Washington, DC

The Honorable Hilda L. Solis
Secretary
Department of Labor
Washington, DC

Inez Tenenbaum, M.Ed.
Chairman
Consumer Product Safety Commission
Bethesda, MD

Jonathan Woodson, M.D.
Assistant Secretary of Defense for Health Affairs
The Pentagon
Washington, DC

National Cancer Advisory Board (Continued)

Alternates to Ex Officio Members

Michael A. Babich, Ph.D.
Directorate for Epidemiology and Health Sciences
Consumer Product Safety Commission
Bethesda, MD
(Ms. Inez Tenenbaum- CPSC)

Patricia Bray, M.D., M.P.H.
Acting Director, Office of Occupational Medicine
OSHA / Department of Labor
Washington, DC
(The Honorable Hilda L. Solis– DOL)

Michael Kelley, M.D., F.A.C.P.
National Program Director for Oncology
Veterans Health Administration
Department of Veterans Affairs
Durham, NC
(The Honorable Dr. Michael J. Kussman)

Aubrey Miller, M.D.
Senior Medical Officer
National Institute of Environmental Health Sciences
National Institutes of Health
Bethesda, MD
(Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S.- NIEHS)

Richard Pazdur, M.D.
Division Director
Division of Oncology Drugs
Food and Drug Administration
Rockville, MD
(Margaret A. Hamburg, M.D. - FDA)

John F. Potter, M.D.
Director
United States Military Cancer Institute
Walter Reed National Military Medical Institute
Bethesda, MD
(Jonathan Woodson, M.D. - DHA)

R. Julian Preston, Ph.D.
Associate Director for Health
Environmental Protection Agency
Research Triangle Park, NC
(Lisa Jackson, M.S. - EPA)

Michael Stebbins, Ph.D.
Assistant Director, Biotechnology
Office of Science and Technology Policy
Executive Office of the President
Washington, DC
(John P. Holdren, Ph.D. –OSTP)

Marie H. Sweeney, Ph.D., M.P.H.
Chief
Surveillance Branch
Division of Surveillance
Hazard Evaluations & Field Studies,
National Institute for Occupational Safety and Health
Cincinnati, Ohio
(John Howard, M.D., M.P.H., J.D., LL.M.- NIOSH)

Lawrence A. Tabak, D.D.S., Ph.D.
Principal Deputy Director
National Institutes of Health
Bethesda, MD
(Francis S. Collins, M.D., Ph.D.)

Sharlene Weatherwax, Ph.D.
Director
Biological Systems Sciences Division
Office of Biological and Environmental Research
Office of Science
U.S. Department of Energy
Washington, DC
(Anna Palmisano, Ph.D. - DOE)

Note: Bold print represents Ex Officio Members

NCI-Frederick Advisory Committee (NFAC)

Membership and Term

Chairperson

2013 Zach W. Hall, Ph.D.
President Emeritus
Institute for Regenerative Medicine
University of California, San Francisco
Wilson, WY 83014

2014 J. Carl Barrett, Ph.D.
Vice-President
Translational Sciences Onc iMed
AstraZeneca
Waltham, MA 02451

2013 David Botstein, Ph.D.
Anthony B. Evnin Professor of Genomics
Department of Molecular Biology
Director
Lewis-Sigler Institute
Princeton University
Princeton, NJ 08544

2016 Vicki L. Colvin, Ph.D.*
Vice-Provost
Kenneth S. Pitzer-Schlimberger
Professor of Chemistry
Rice University
Houston, TX 77005

2015 Levi A. Garraway, M.D., Ph.D.
Assistant Professor of Medicine
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA 02115

2013 Joe W. Gray, Ph.D.
Gordon Moore Endowed Chair
Chair, Department of Biomedical Engineering
Director, OHSU Center for Spatial Systems
Biomedicine
Oregon Health and Science University
Portland, OR

2015 Beatrice H. Hahn, M.D.
Professor of Medicine
Division of Hematology/Oncology
University of Pennsylvania
Philadelphia, PA 19104

2014 Jennifer A. Pietenpol, Ph.D.
Director
Vanderbilt-Ingram Cancer Center
B.F. Byrd, Jr. Professor of Oncology
Professor of Biochemistry
Vanderbilt University Medical Center
Nashville, TN 37232

2014 Steven T. Rosen, M.D., F.A.C.P.
Genevieve Teuton Professor of Medicine
Department of Medicine
Feinberg School of Medicine
Director, Robert H. Lurie Comprehensive
Cancer Center
Northwestern University
Robert H. Lurie Medical Research Center
Chicago, IL 60611

2015 Cheryl L. Willman, M.D.
Maurice and Marguerite Liberman
Distinguished Chair in Cancer Research
Director and CEO
Cancer Research and Treatment Center
University of New Mexico
Albuquerque, NM 87131

2014 Monica J. Justice, Ph.D.
Professor
Department of Molecular and Human Genetics
Baylor College of Medicine
Houston, TX 77030

2013 Thomas A. Look, M.D.
Vice Chair for Research
Department of Pediatric Oncology
Dana-Farber Cancer Institute
Boston, MA 02115

2015 Lawrence J. Marnett, Ph.D.
Director
Vanderbilt Institute of Chemical Biology
Mary Geddes Stahlman Professor of Biochemistry
Chemistry, and Pharmacology
Director, A.B. Hancock Jr. Memorial Laboratory
Director, Vanderbilt Institute of Chemical Biology
Vanderbilt University Medical Center
Nashville, TN 37232

NCI-Frederick Advisory Committee (NFAC) (Continued)

Membership and Term

2013 Jill P. Mesirov, Ph.D.
Chief Informatics Officer
Broad Institute of MIT and Harvard
Director
Computational Biology and Bioinformatics
Cambridge, MA 02142

2015 Garry P. Nolan, Ph.D.
Rachford and Carlota A. Harris Professor
Baxter Laboratory in Genetic Pharmacology
Department of Microbiology & Immunology
Director, Stanford University Proteomics Center
Stanford University
Stanford, CA 94305

2015 Kenneth Olden, Ph.D., Sc.D., L.H.D.
Director
National Center for Environmental Assessment
Office of Research and Development
Environmental Protection Agency
Washington, DC 20460

2016 Kenneth J. Pienta, M.D.
Associate Vice President for Research,
Health Sciences
Professor of Internal Medicine and Urology
The University of Michigan
Ann Arbor, MI 48109

Executive Secretary
Thomas M. Vollberg, Sr., Ph.D.

* Newly appointed member pending personnel paperwork

Ex Officio Members

John Czajkowski, M.P.A.
Deputy Director for Management
National Cancer Institute
National Institutes of Health
Bethesda, MD

James H. Doroshow, M.D.
Deputy Director
Clinical and Translational Research
National Cancer Institute
National Institutes of Health
Bethesda, MD

Paulette S. Gray, Ph.D.
Director
Division of Extramural Activities
National Cancer Institute
National Institutes of Health
Bethesda, MD

Douglas R. Lowy, M.D.
Deputy Director
National Cancer Institute
National Institutes of Health
Bethesda, MD

Alan S. Rabson, M.D.
Deputy Director
National Cancer Institute
National Institutes of Health
Bethesda, MD

Craig W. Reynolds, Ph.D.
Associate Director
National Cancer Institute
Frederick National Laboratory for
Cancer Research
National Institutes of Health
Frederick, MD

Margaret A. Tucker, M.D.
Acting Director
Division of Cancer Epidemiology
and Genetics
National Cancer Institute
National Institutes of Health
Bethesda, MD

Robert H. Wiltrout, Ph.D.
Director
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, MD

Clinical Trials and Translational Research Advisory Committee (CTAC)

Membership and Term

Chair

2012 **James L. Abbruzzese, M.D., F.A.C.P.**
Chairman
Department of Gastrointestinal Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, TX

2013 **Peter C. Adamson, M.D.**
Chair, Children's Oncology Group
Chief, Division of Clinical Pharmacology & Therapeutics
The Children's Hospital of Philadelphia
University of Pennsylvania
Philadelphia, PA

2014 **Susan G. Arbuck, M.D., M.Sc., F.A.C.P.**
President
Susan G. Arbuck, M.D., LLC
Potomac, MD

2014 **Monica M. Bertagnolli, M.D.**
Professor of Surgery Harvard Medical School
Brigham & Women's Hospital
Dana-Farber Cancer Institute
Boston, MA

2013 **Susan G. Braun (DCLG)**
Executive Director
Commonwealth
Bolinas, CA

2012 **Curt Civin, M.D. (BSA)**
Associate Dean of Research
Professor of Pediatrics
Director
Center for Stem Cell Biology and Regenerative Medicine
University of Maryland School of Medicine
Baltimore, MD

2012 **Kenneth H. Cowan, M.D., Ph.D.**
Director
Eppley Institute for Cancer Research
University of Nebraska Medical Center
Omaha, NE

2015 **Kevin J. Cullen, M.D. (NCAB)**
Director
University of Maryland Greenebaum Cancer Center
Baltimore, MD

2015 **Nancy E. Davidson, M.D.**
Director
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, PA

2013 **Olivera J. Finn, Ph.D.**
Distinguished Professor and Chair
University of Pittsburgh School of Medicine
Pittsburgh, PA

2015 **J. Phillip Kuebler, M.D., Ph.D.**
Principal Investigator
Columbus Oncology Associates, Inc.
Columbus, OH

2013 **Scott M. Lippman, M.D.**
Professor and Chair
Department of Thoracic/Head and Neck Medical Oncology
The U. of Texas M.D. Anderson Cancer Center
Houston, TX

2014 **Mary S. McCabe, R.N.**
Director
Cancer Survivorship Program
Memorial Sloan Kettering Cancer Center
New York, NY

2016 **Edith P. Mitchell, M.D., FACP***
Director, Center for Elimination of Cancer Disparities
Kimmel Cancer Center at Jefferson
Thomas Jefferson University
Philadelphia, PA

2016 **Nikhil C. Munshi, M.D.***
Associate Professor of Medicine
Hematologic Oncology Treatment Center
Dana Farber Cancer Institute
Boston, MA

2014 **Lisa A. Newman, M.D., M.P.H., F.A.C.S.**
Professor of Surgery and Director, Breast Cancer Center and Multidisciplinary Breast Fellowship Program
U. of Michigan Comprehensive Cancer Center
Ann Arbor, MI

2013 **Nancy Roach (BSC)**
Consumer Advocate
C3: Colorectal Cancer Coalition
Hood River, OR

2013 **Daniel J. Sargent, Ph.D.**
Director
Cancer Center Statistics
Professor
Mayo Clinic College of Medicine
Mayo Clinic Foundation
Rochester, MN

Clinical Trials and Translational Research Advisory Committee (Continued)

Membership and Term

2013 **Mitchell D. Schnall, M.D., Ph.D.**
Matthew J. Wilson Professor
University of Pennsylvania Medical Center
Philadelphia, PA

2014 **Peter G. Shields, M.D.**
Deputy Director
Comprehensive Cancer Center
Professor
College of Medicine
The Ohio State University Medical Center
Columbus, OH

2015 **George W. Sledge, Jr., M.D.**
Professor
Departments of Medicine and Pathology
Co-leader
Breast Cancer Program
Indiana University Cancer Center
Indianapolis, IN

2016 **Chris H.M. Takimoto, M.D., Ph.D., FACP***
Vice President
Translational Medicine Early Development
Oncology Therapeutics Area
Janessen Research and Development
Pharmaceutical Companies of Johnson and Johnson
Radnor, PA

2012 **Joel E. Tepper, M.D.**
Hector MacLean Distinguished Professor of Cancer Research
Department of Radiation Oncology
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

2014 **Gillian M. Thomas, M.D., FRCPC, FRCR**
Professor
Department of Radiation Oncology
Department of Obstetrics and Gynecology
University of Toronto
Odette Cancer Centre
Sunnybrook Health Sciences Centre
Toronto, Ontario
Canada

2014 **Frank M. Torti, M.D., M.P.H. (BSA)**
Vice President for Strategic Programs
Wake Forest Baptist Medical Center
Chair
Cancer Biology
Charles L. Spurr Professor of Medicine
Director

2014 **Miguel A. Villalona-Calero, M.D.**
Professor of Medical Oncology
Division of Hematology and Oncology
The Ohio State University
Columbus, OH

2015 **George J. Weiner, M.D.**
C.E. Block Chair of Cancer Research
Professor
Department of Internal Medicine
Director
Holden Comprehensive Cancer Center
Iowa City, Iowa

Executive Secretary
Sheila A. Prindiville, M.D., MPH

*Ad hoc Members

Clinical Trials and Translational Research Advisory Committee (Continued)

Ex Officio Members

James H. Doroshow, M.D.
Deputy Director
Clinical and Translational Research
National Cancer Institute
National Institutes of Health
Bethesda, MD

Paulette Gray, Ph.D.
Director
Division of Extramural Activities
National Cancer Institute
National Institutes of Health
Bethesda, MD

Rosemarie Hakim, Ph.D., M.S.
Epidemiologist
Centers for Medicare and Medicaid Services
Baltimore, MD

Lee Helman, M.D.
Chief
Pediatric Oncology Branch
Scientific Director for Clinical Research
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, MD

Michael J. Kelley, M.D., F.A.C.P.
National Program Director for Oncology
Veterans Health Administration
Department of Veterans Affairs
Washington, DC

Richard Pazdur, M.D., F.A.C.P.
Director
Division of Oncology Drug Products
U.S. Food and Drug Administration
Rockville, MD

TBD
United States Military Cancer Institute
Walter Reed National Military Medical Institute
Bethesda, MD

Alan Rabson, M.D.
Deputy Director
National Cancer Institute
National Institutes of Health
Bethesda, MD

Clinical Trials and Translational Research Advisory Committee (Continued)

Ad Hoc Subcommittee

NCI Clinical Trials Strategic Planning Ad Hoc Subcommittee

James L. Abbruzzese, M.D. (Chair)
Chairman
Department of Gastrointestinal Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, TX

Nancy E. Davidson, M.D.
Director
University of Pittsburgh Cancer Institute
Unversity of Pittsburgh
Pittsburgh, PA

Scott M. Lippman, M.D.
Director
UC San Diego Moores Cancer Center
La Jolla, CA

Nancy A. Roach (BSC)
Consumer Advocate
C3: Colorectal Cancer Coalition
Hood River, OR

Joel E. Tepper, M.D.
Hector MacLean Distinguished Professor of Cancer Research
Department of Radiation Oncology
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC

George J. Weiner, M.D.
C.E. Block Chair of Cancer Research
Professor
Department of Internal Medicine
Director
Holden Comprehensive Cancer Center
Iowa City, Iowa

NCI Liaisons

Jeffrey S. Abrams, M.D.
Acting Director
Division of Cancer Treatment and Diagnosis
National Cancer Institute

James H. Doroshow, M.D.
Deputy Director
National Cancer Institute
National Institutes of Health
Bethesda, MD

Leslie G. Ford, M.D.
Associate Director for Clinical Research
Office of the Director
National Cancer Institute
National Institutes of Health
Bethesda, MD

Lori Minasian, M.D., F.A.C.P.
Acting Director
Division of Cancer Prevention
National Cancer Institute

Executive Secretary
Sheila A. Prindiville, M.D., M.P.H.
Director
Coodinating Center for Clinical Trials
Office of the Director
National Cancer Institute
National Institutes of Health
Bethesda, MD

CTAC Working Groups

Pancreatic Cancer Working Group

NCI National Clinical Trials Network (NCTN) Working Group

Board of Scientific Counselors

Intramural Programs

Clinical Sciences and Epidemiology

Appointees	Expiration of Appointment
Chair - Ethan Dmitrovsky, M.D.	**2013**
Edgar Ben-Josef, M.D.	2014
Jonine L. Bernstein, Ph.D. *	2017
Arthur W. Blackstock, Jr., M.D.	2016
Tim Byers, M.D.	2015
Susan Chang, M.D.	2013
Susan Cohn, M.D.*	2017
Marc T. Goodman, Ph.D.	2015
Bernard Harlow, Ph.D.	2014
Carl June, M.D.	2014
Karen L. Kelly, M.D.	2015
Hongzhe Lee, Ph.D.	2016
Alexandra M. Levine, M.D.	2015
Sanford Markowitz, M.D., Ph.D.	2016
Augusto Ochoa, M.D.	2014
Kenneth Offit, M.D.	2016
Raphael E. Pollock, M.D., Ph.D.	2016
David Poplack, M.D.	2014
Jeremy Rich, M.D.*	2017
Nancy Roach	2013
Thomas Rohan, M.D., Ph.D.	2014
Thomas A. Sellers, Ph.D.	2013
Darryl K. Shibata, M.D.	2015
Walter Stadler, M.D.*	2017
Robert E. Tigelaar, M.D.	2013
Walter J. Urba, M.D., Ph.D.	2013
Elizabeth Ward, Ph.D.	2014
Louis Weiner, M.D.*	2017
George Wilding, M.D.	2016
Cheryl L. Willman, M.D.	2015
Executive Secretary - Brian Wojcik, Ph.D.	

Basic Sciences

Appointees	Expiration of Appointment
Chair - Joan W. Conaway, Ph.D.	**2015**
Paul D. Bieniasz, Ph.D.	2014
John C. Cambier, Ph.D.	2015
Lawrence Corey, M.D.	2014
Sara A. Courtneidge, Ph.D.	2016
Norman Drinkwater, Ph.D.	2014
Errol Friedberg, M.D.	2014
Joanna Groden, Ph.D.	2016
Daria J. Hazuda, Ph.D.	2015
Eric Hunter, Ph.D.	2015
Stephen D. Hursting, Ph.D.	2017
Chris M. Ireland, Ph.D.	2013
Alexandra L. Joyner, Ph.D.	2016
Marcelo G. Kazanietz, Ph.D.	2015
Robert E. Lewis, Ph.D.	2016
Jonathan D. Licht, M.D.	2014
A. Thomas Look, M.D.	2013
Ian G. Macara, Ph.D.	2014
Roeland Nusse, Ph.D.	2017
Suzanne Ostrand-Rosenberg, Ph.D.	2014
Thomas L. Poulos, Ph.D.	2015
James H. Prestegard, Ph.D.	2013
Kenneth L. Rock, M.D.	2015
James A. Wells, Ph.D.	2016
Tzyy-Choou Wu, M.D., Ph.D.	2017
Wayne M. Yokoyama, M.D.	2016
Virginia A. Zakian, Ph.D.	2015
Dong-Er Zhang, Ph.D.	2017
Executive Secretary - Florence E. Farber, Ph.D.	

Board of Scientific Advisors

Extramural Programs

Chair - Todd R. Golub, M.D.	**2015**
Francis Ali-Osman, D.Sc.	2016
Ethan M. Basch, M.D., M.Sc.*	2017
Sangeeta N. Bhatia, M.D., Ph.D.	2016
Andrea Califano, Ph.D.	2013
Arul M. Chinnaiyan, M.D., Ph.D.	2015
Curt I. Civin, M.D.	2015
Graham A. Colditz, M.D., Dr.Ph.*	2017
Chi V. Dang, M.D., Ph.D.	2014
Robert B. Diasio, M.D.	2013
Daniel A. DiMaio, M.D., Ph.D.*	2017
Jeffrey A. Drebin, M.D., Ph.D., F.A.C.S.	2014
Brian J. Druker, M.D.	2016
Karen M. Emmons, Ph.D.	2016
Betty Ferrell, Ph.D., RN, F.A.A.N.	2015
Kathleen M. Foley, M.D.	2013
Stanton L. Gerson, M.D.	2016
Joe W. Gray, Ph.D.	2013
Chanita Hughes-Halbert, Ph.D.	2017
Joshua LaBaer, M.D., Ph.D.	2014
Theodore S. Lawrence, M.D., Ph.D.	2016
Mr. Donald Listwin	2014
Maria E. Martinez, Ph.D., M.P.H.	2015
Luis F. Parada, Ph.D.	2016
Martine F. Roussel (Sherr), Ph.D.*	2017
Kevin M. Shannon, M.D.*	2017
Mary L. Smith, J.D., M.B.A.*	2017
Lincoln Stein, M.D., Ph.D.	2016
Bruce W. Stillman, Ph.D.	2015
Louise C. Strong, M.D.	2013
Frank M. Torti, M.D., M.P.H.	2014
Gregory L. Verdine, Ph.D.	2016
Cheryl L. Walker, Ph.D., A.T.S., F.A.A.N.*	2017
Irving L. Weissman, M.D.	2015
Executive Secretary - Paulette S. Gray, Ph.D.	

* Newly appointed member pending personnel

President's Cancer Panel

Barbara K. Rimer, DrPH, MPH 2012
Dean and Alumni Distinguished Professor
Gillings School of Global Public Health
The University of North Carolina at Chapel Hill
Chapel Hill, NC 27599

Owen N. Witte, M.D. 2014
Director
Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
Investigator, Howard Hughes Medical Institute
University of California, Los Angeles
Los Angeles, CA 90095

Hill Harper, J.D. 2013
Cancer Survivor
4 Time New York Times Best-Selling Author, Actor, and Philanthropist
Hollywood, CA

Abby B. Sandler, Ph.D.
Executive Secretary
NCI Office of the Director
9000 Rockville Pike
Bldg. 31, Room B2B37
Bethesda, MD 20892-2590

Scientific Program Leaders (SPL) Members

Harold Varmus, M.D.
Director

Jeff Abrams, M.D.
Acting Director for Clinical Research, Division of Cancer Treatment and Diagnosis

Stephen J. Chanock, M.D.
Acting Co-Director, Center for Cancer Genomics

Robert T. Croyle, Ph.D.
Director, Division of Cancer Control and Population Sciences

John Czajkowski
Deputy Director for Management

James H. Doroshow, M.D.
Deputy Director for Clinical and Translational Research

Paulette S. Gray, Ph.D.
Director, Division of Extramural Activities

Peter Greenwald, M.D., Dr.Ph
Associate Director for Prevention

Lee Helman, M.D.
Scientific Director for Clinical Research, CCR

George Komatsoulis
Acting Director, Center for Biomedical Informatics and Information Technology

Barnett S. Kramer, M.D., MPH
Director, Division of Cancer Prevention

Douglas Lowy, M.D.
Deputy Director

Alan S. Rabson, M.D.
Deputy Director

Dinah S. Singer, Ph.D.
Director, Division of Cancer Biology

Sanya A. Springfield, Ph.D.
Director, Center to Reduce Cancer Health Disparities

Louis M. Staudt, M.D.
Acting Co-Director, Center for Cancer Genomics

Joseph Tomaszewski, Ph.D.
Acting Director for Preclinical Research, Division of Cancer Treatment and Diagnosis

Ted Trimble, M.D., MPH
Director, Center for Global Health

Margaret A. Tucker, M.D.
Acting Director, Division of Cancer Epidemiology and Genetics

Michael Weingarten
Director, SBIR Development Center

Linda Weiss, Ph.D.
Director, Cancer Centers

Jonathan Wiest, Ph.D.
Director, Center for Cancer Training

Robert H. Wiltrout, Ph.D.
Director, Center for Cancer Research

Robert Yarchoan, M.D.
Director, Office of HIV & AIDS Malignancy

Joy Wiszneauckas
Executive Secretary

NCI Director's Consumer Liaison Group

Ms. Gwen Darien, Chair **2013**
Chari, DCLG

Dr. Jeff Allen **2013**
Friends of Cancer Research

Mr. David Arons **2016**
National Brain Tumor Society

Ms. Susan Braun **2013**
The V Foundation for Cancer Research

Dr. Adam Clark **2015**
U.S. Department of Health and Human Services

Ms. Andrea Ferris **2015**
LUNGevity

Ms. Joya Delgado Harris **2015**
American Cancer Society

Dr. Michelle McMurry-Heath **2014**
U.S. Food and Drug Administration

Ms. Linda House **2015**
Cancer Support Community

Mr. Jeff Kaufman **2015**
Adenoid Cystic Carcinoma Research Foundation

Mr. Jon Retzlaff **2014**
American Association for Cancer Research

Mr. Josh Sommer **2014**
Chordoma Foundation

Mr. Max Wallace **2013**
Accelerate Brain Cancer Cure

Ms. Kelli Marciel
Executive Secretary

Director, Office of Advocacy Relations
National Cancer Institute
31 Center Drive, Room 10A28
Bethesda, MD 20892-2580

National Cancer Institute



These organizational charts reflects the operational structure of NCI. Official organizational chart can be found at http://oma.od.nih.gov/manualchapters/management/1123/nci.pdf


National Cancer Institute
Office of the Director
Harold Varmus, M.D.
Director
301-496-5615
Deputy Directors
Deputy Director
Dr. Alan Rabson
301-496-1927
Deputy Director
Dr. Doug Lowy
301-827-5699
Deputy Director
Clinical and Translational Research
Dr. Jim Doroshow
301-496-5615
Deputy Director for Management
Mr. John Czajkowski
301-435-2455
Office of Public Affairs and Research Communications
Director
Mr. Rick Borchelt
301-435-5709
Associate Director for Prevention
Dr. Peter Greenwald
301-451-2474
Special Assistant to the Director
Ms. Amy Bulman
301-496-9723
Office of Advocacy Relations
Director
Ms. Amy Bulman
301-496-9723
Institute Review Office
Chief
Dr. Mehrdad Tondravi
301-496-7628
Office of Management
Deputy Director for Management
(Executive Officer)
Mr. John Czajkowski
301-435-2455
Center for Biomedical Informatics and Information Technology
Acting Director
Dr. George Komatsoulis
301-451-2881
Office of Science Planning and Assessment
Acting Director
Dr. Margaret Ames
301-402-7519
Office of Communications and Education
Director
Dr. Lenora Johnson
301-451-4056
Center for Cancer Genomics
Acting Directors
Dr. Stephen J. Chanock
Dr. Louis Staudt
301-435-7559
Office of Cancer Centers
Director
Dr. Linda Weiss
301-496-8531
Center for Strategic Scientific Initiatives
Acting Director
Dr. Doug Lowy
301-827-5699
Center to Reduce Cancer Health Disparities
Director
Dr. Sanya A. Springfield
301-496-8589
Center for Cancer Training
Director
Dr. Jonathan Wiest
301-435-9030
Coordinating Center for Clinical Trials
Director
Dr. Sheila Prindiville
301-451-5041
Office of HIV and AIDS Malignancy
Director
Dr. Robert Yarchoan
301-496-0328
SBIR Development Center
Director
Mr. Michael S. Weingarten
301-496-4413
NCI-Frederick Office of Scientific Operations
Associate Director
Dr. Craig Reynolds
301-846-5693
Center for Global Health
Director
Dr. Ted Trimble
301-496-1045


Office of Management
Deputy Director for Management
(Executive Officer)
Mr. John Czajkowski
301-435-2455
Deputy Executive Officer
Ms. Anne Lubenow
301-435-7780
Employee Relations Group
Gwyn Collins
301-435-3620
Administrative Resource Center - OD
Director
Ms. Cathy Ng
301-435-2961
Administrative Resource Center - DCTD
Director
Mr. Joe Jenkins
301-594-5965
Administrative Resource Center – DCCPS/DCP
Director
Ms. Joy Osborne
301-496-0010
Administrative Resource Center – DCB/DEA
Director
Ms. Bridgette Tobiassen
301-496-2871
Technology Transfer Center
Director
Ms. Karen Maurey
301-496-0477
Office of Budget and Finance
Acting Director
Ms. Karen Colbert
301-496-5803
Office of Government and Congressional Relations
Director
Ms. Susan Erickson
301-496-5217
Office of Ethics
Director/DEC
Ms. Nancy O'Hanlon
301-496-1148
Deputy Executive Officer
Ms. Donna Siegle
301-594-7507
Office of Workforce Management and Development
Director
Ms. Christina Bruce
301-435-8524
Office of Grants Administration
Director
Ms. Crystal Wolfrey.
301-496-8634
Office of Acquisitions
Director
Ms. Kristen Mistichelli
301-435-3810
Office of Extramural Finance and Information Analysis
Director
Mr. Nelson Garcia
301-435-5205
Office of Management Policy and Compliance
Director
Ms. Roxane Kerr
301-435-5786
Office of Space and Facilities Management
Director
Mr. Daryl Paunil
301-496-1858
Administrative Resource Center - DCEG
Director
Mr. Roberto Minutillo
301-594-7510
IT Resource Center
Director
Mr. Bob Barber
301-496-1962
Administrative Resource Center - OM
Director
Ms. Sue Kiser
301-435-2065
Administrative Resource Center - CCR
Director
Ms. Lori Holliday
301-496-6174
Support Services Branch
Chief
Mr. Michael Tucker
301-496-4010
Clinical ARC
ARC Manager
Mr. Patrick Miller
301-435-2509
Basic ARC
ARC Manager
Ms. Lisa Kelly
301-496-1841
Frederick ARC
ARC Manager
Ms. Tanya Sappington
301-846-1072
Workforce Management Branch
Branch Lead
Ms. Susan Ettehadieh
301-435-7978
Training and Organizational Development Branch
Branch Lead
Ms. Yasmin Nasser
301-435-8524
Programs and Services Branch
Branch Lead
Mr. Leon Espinoza
301-435-8524
Branch D
Vacant
Office of Grants Administration
Deputy Director
Ms. Crystal Wolfrey
301-496-8634
Grants Operations Branch
Chief
Mr. Jason Ford
301-594-2497
Grants Portfolio Management Branch A
Chief
Mr. Sean Hine
301-846-1005
Grants Portfolio Management Branch B
Chief
Mr. Shane Woodward
301-846-1017
Grants Portfolio Management Branch C
Chief
Ms. Carol Perry
301-496-7205
Epidemiology, Therapeutics and Sciences Branch
Chief
Ms. Jackie Holden
301-435-3820
Prevention, Control and Population Sciences Branch
Chief
Ms. Teresa Baughman
301-435-3800
Strategic Acquisition Branch
Acting Chief
Ms. Anita Hughes
301-402-4511
Treatment and Support Branch
Chief
Mr. Matthew Packard
301-624-8742
Management Operations and Support Branch
Acting Chief
Mr. Steven Davis
301-846-1112
Financial Analysis Branch
Chief
Ms. Tenille McCatty
301-435-5217
Information Analysis and Applications Branch
Chief
Ms. Carol L. Smith
301-435-5215
Management Support Branch
Chief
Ms. Alesha Holliday
301-594-6008
Quality Management/ Program Integrity Branch
Chief
Ms. Laura Larson
301-402-7520
Project Management Branch
Chief
Mr. Jeffrey Greenblatt
301-496-0136
Business Operations Branch
Chief
Mr. Steve Kelley
301-451-4066


Center for Biomedical Informatics and Information Technology
Acting Director
Dr. George Komatsoulis
301-451-2881
Technical Operations
Director
Mr. Eric Williams
301-594-0764
Scientific Programs
Director
Vacant
Information Management
Director
Mr. Christo Andonyadis
301-480-6187
Research and Development
Director
Mr. Daoud Meerzaman
301-495-0180
Office of Science Planning and Assessment
Acting Director
Dr. Margaret Ames
301-402-7519
Deputy Director
Vacant
Women's Health
Officer
Dr. Karen Parker
301-451-9462
Science Planning Branch
Chief
Ms. Karen Parker
301-451-9462
Program Assessment Branch
Chief
Dr. James Corrigan
301-435-3856
Program Implementation Branch
Chief
Vacant


Office of Communications and Education
Director
Dr. Lenora Johnson
301-451-4056
Associate Director
Ms. Nelvis C. Castro
301-435-278
Multicultural and International Communications
Communications Planning and Coordination Branch
Acting Chief
Ms. Sabrina Islam-Raham
301-451-9829
Business Operations Branch
Chief
Mr. Kevin Davis
301-594-5713
Communications Technology Branch
Chief
Mr. Jonathon Cho
301-594-0865
Office of Public Information and Resource Management
Associate Director
Ms. Mary Anne Bright
301-594-9048
Office of Partnerships and Dissemination Initiatives
Associate Director
Ms. Madeline LaPorta
301-594-8025
Office of Communications Services
Associate Director
Ms. Donna Bonner
301-435-5780
Office of Market Research and Evaluation
Acting Associate Director
Dr. Lenora Johnson
Office of Cancer Content Management
Associate Director
Dr. Richard Manrow
301-435-2789
International Cancer Research Databank Branch
Acting Chief
Dr. Margaret Beckwith
301-594-2718
Cancer Publications Branch
Chief
Dr. Rebecca Chasan
301-451-9567


Center for Cancer Genomics
Acting Director
Dr. Stephen J. Chanock
301-435-7559
Acting Director
Dr. Louis Staudt
301-402-1892
Acting Deputy Director
Dr. Jerry Lee
301-496-1045
Office of Cancer Genomics
Director
Dr. Daniela S. Gerhard
301-451-8027
The Cancer Genome Atlas Program Office
Director
Dr. Kenna Shaw
301-435-3864


Center for Strategic Scientific Initiatives
Acting Director
Dr. Doug Lowy
301-827-5699
Deputy Director
Dr. Jerry Lee
301-496-1045
Office of Cancer Nanotechnology Research
Director
Dr. Piotr Grodzinski
301-451-8983
Office of Cancer Clinical Proteomics Research
Director
Dr. Henry Rodriguez
301-451-8883
Knowledge Management and Special Projects Branch
Chief
Ms. Lisa Krueger
301-451-5115
Office of Physical Sciences-Oncology
Director
Dr. Larry Nagahara
301-451-3388


Center to Reduce Cancer Health Disparities
Director
Dr. Sanya Springfield
301-496-8589
Deputy Director
Vacant
Disparities Research Branch
Chief
Dr. Avraham Rasooly
301-435-9213
Diversity Training Branch
Chief
H. Nelson Aguila
301-496-8589


Center for Cancer Research
Office of the Director
Director
Dr. Robert Wiltrout
301-496-4345
Dr. Lee Helman
Scientific Director for Clinical Research
301-496-4346
Dr. Lee Helman
Deputy Director
301-496-4346
Dr. Glenn Merlino
Deputy Director
301-496-4270
Dr. Mark Udey
Deputy Director
301-496-2481
Dr. Ronald Gress
Deputy Director
301-496-1791
Dr. William Dahut
Deputy Director
301-435-8183
Dermatology Branch
Chief
Dr. Mark Udey
301-496-1741
Experimental Transplantational and Immunology Branch
Chief
Dr. Ronald Gress
301-496-1791
Metabolism Branch
Chief
Dr. Thomas Waldmann
301-496-6653
Office of Clinical Director
Chief
Dr. William Dahut
301-435-8183
Medical Oncology Branch
Chief
Dr. Giuseppe Giaccone
301-496-4257
Surgery Branch
Chief
Dr. Steven Rosenberg
301-496-4164
Gene Regulation and Chromosome Biology Laboratory
Chief
Dr. Jeffrey Strathern
301-846-1274
Laboratory of Cell Biology
Chief
Dr. Michael Gottesman
301-496-1530
Laboratory of Cellular and Molecular Biology
Chief
Dr. Larry Samelson
301-496-9683
Laboratory of Human Carcinogenesis
Chief
Dr. Curtis Harris
301-496-2048
Laboratory of Experimental Carcinogenesis
Chief
Dr. Snorri Thorgeirsson
301-496-1935
Laboratory of Molecular Pharmacology
Chief
Dr. Yves Pommier
301-496-5944
Laboratory of Cellular Oncology
Chief
Dr. Douglas Lowy
301-496-9513
Cell and Cancer Biology Branch
Chief
Dr. Kathleen Kelly
301-435-4651
Laboratory of Pathology
Chief
Dr. J. Carl Oberholtzer
301-435-5152
Radiation Oncology Branch
Chief
Dr. Kevin Camphausen
301-496-5457
Radiation Biology Branch
Chief
Dr. James Mitchell
301-496-7511
Cancer Genetics Branch
Chief
Dr. Paul Meltzer
301-594-5283
Urologic Oncology Branch
Chief
Dr. W. Marston Linehan
301-496-6353
Neuro-Oncology Branch
Chief
Vacant
Laboratory of Tumor Immunology and Biology
Chief
Dr. Jeffrey Schlom
301-496-4343
Endocrine Oncology Branch
Chief
Dr. Electron Kebebew
301-496-5049
Molecular Imaging Program
Chief
Dr. Peter Choyke
301-451-6039
Pediatric Oncology Branch
Chief
Dr. Crystal Mackall
301-402-5940
HIV and AIDS Malignancy Branch
Chief
Dr. Robert Yarchoan
301-496-0328

Center for Cancer Research
Office of the Director

Director
Dr. Robert Wiltrout
301-496-4345

Dr. Lee Helman
Scientific Director for Clinical Research
301-496-4346

Dr. Jeffrey Strathern
Deputy Director
301-846-1274

Dr. Lawrence Samelson
Deputy Director
301-496-4346

Cancer and Developmental Biology Laboratory
Chief
Dr. Alan Perantoni
301-846-6529

HIV Drug Resistance Program
Director
Dr. Stephen Hughes

HIV DRP Retroviral Replication Laboratory
Chief
Dr. Stephen Hughes

Host Virus Interaction Branch
Acting Chief
Dr. Stephen Hughes
301-846-1619

Cancer and Inflammation Program
Director
Dr. Giorgio Trinchieri

Laboratory of Experimental Immunology
Chief
Dr. Giorgio Trinchieri
301-846-1323

Laboratory of Molecular Immunoregulation
Chief
Dr. Joost Oppenheim
301-846-1551

Laboratory of Cancer Prevention
Chief
Dr. Nancy Colburn
301-846-1342

Laboratory of Cell and Developmental Signaling
Chief
Dr. Debbie Morrison
301-846-1733

Molecular Discovery Program
Acting Director
Dr. Jeffrey Strathern
301-846-1274

Chemical Biology Laboratory
Chief
Dr. Joel Schneider
301-846-5954

Molecular Targets Laboratory
Chief
Dr. James McMahon
301-846-5391

Structural Biophysics Laboratory
Chief
Dr. R. Andrew Byrd
301-846-1407

CCR Nanobiology Program
Chief
Dr. Robert Blumenthal
301-846-5532

Laboratory of Protein Dynamics and Signaling
Chief
Dr. Allan Weissman
301-846-1222

Macromolecular Crystallography Laboratory
Chief
Dr. Alexander Wlodawer
301-846-5036

Mouse Cancer Genetics Program
Co - Directors
Dr. Lino Tessarollo
301-846-1202
Dr. Shyam Sharan
301-846-5140

Laboratory of Genomic Diversity
Acting Chief
Dr. Jeffrey Strathern
301-846-1274

Experimental Immunology Branch
Chief
Dr. Alfred Singer
301-496-5461

Laboratory of Cancer Biology and Genetics
Co-Chiefs
Dr. Stuart Yuspa
301-496-2162
Dr. Glenn Merlino
301-496-4270

Laboratory of Biochemistry and Molecular Biology
Chief
Dr. Shiv Grewal
301-594-6389

Laboratory of Immune Cell Biology
Chief
Dr. Jonathan Ashwell
301-496-4931

Laboratory of Molecular Biology
Co - Chiefs
Dr. Ira Pastan
301-496-4797
Dr, Susan Gottesman
301-496-3524

Krietman Clinical Component Deputy
Dr. Ron Gress
301-496-1791

Laboratory of Metabolism
Chief
Dr. Frank Gonzalez
301-435-5587

Vaccine Branch
Chief
Dr. Jay Berzofsky
301-496-6874
Clinical Component Deputy
Dr. Ron Gress
301-496-1791

Laboratory of Genome Integrity
Chief
Dr. Andre Nussenweig
301-435-6425

Basic Research Laboratory
Co-Chiefs
Dr. Lawrence Samelson
301-496-4346
Dr. Jeffrey Strathern
301-846-1274

Laboratory of Receptor Biology and Gene Expression
Chief
Dr. Gordon Hager
301-496-9867


Division of Cancer Biology
Office of the Director
Director
Dr. Dinah S. Singer
301-496-8636
Deputy Director
Dr. Dan Gallahan
301-496-8636
Associate Director
Dr. Cheryl Marks
301-594-8778
Associate Director
Dr. Suresh Mohla
301-435-1878
Cancer Etiology Branch
Chief
Dr. Don Blair
301-496-9740
Tumor Biology and Metastasis Branch
Chief
Dr. Suresh Mohla
301-435-1878
Cancer Immunology and Hematology Branch
Chief
Dr. R. Allan Mufson
301-496-7815
DNA and Chromosome Aberrations Branch
Chief
Dr. Judith Mietz
301-496-9326
Cancer Cell Biology Branch
Chief
Dr. Barbara Spalholz
301-496-7028
Structural Biology and Molecular Applications Branch
Chief
Dr. Jennifer Couch
301-435-5226


Division of Cancer Epidemiology and Genetics
Office of the Director
Acting Director
Dr. Margaret A. Tucker
301-496-1611
Deputy Director
Vacant
Office of Communications and Special Initiatives
Chief
Ms. Catherine B. McClave
301-496-6271
Office of Division Operations and Analysis
Chief
Ms. Marianne K. Henderson
301-496-8672
Office of Education
Chief
Dr. Jackie A. Lavigne
301-451-6739
Epidemiology and Biostatistics Program
Director
Dr. Robert N. Hoover
301-496-3004
Human Genetics Program
Director
Dr. Margaret A. Tucker
301-496-4375
Biostatistics Branch
Chief
Dr. Nilanjan Chatterjee
301-402-7933
Hormonal and Reproductive Epidemiology Branch
Chief
Dr. Louise A. Brinton
301-496-1691
Genetic Epidemiology Branch
Chief
Dr. Neil E. Caporaso
301-496-4377
Clinical Genetics Branch
Chief
Dr. Mark H. Greene
301-594-7642
Nutritional Epidemiology Branch
Chief
Vacant
301-496-3004
Occupational and Environmental Epidemiology Branch
Chief
Dr. Debra T. Silverman
301-435-4716
Cancer Genomics Research Laboratory
Director
Dr. Stephen J. Chanock
301-435-7559
Laboratory of Translational Genomics
Chief
Dr. Stephen J. Chanock
301-435-7559
Radiation Epidemiology Branch
Chief
Dr. Martha S. Linet
301-496-6600
Infections and Immunoepidemiology Branch
Chief
Dr. Allan Hildesheim
301-435-3984

Division of Cancer Prevention

Office of the Director

Director
Dr. Barnett Kramer
301-496-6616

Deputy Director
Dr. Lori Minasian
301-496-8541

Associate Director for Clinical Research
Dr. Leslie G. Ford
301-496-0265

Breast & Gynecologic Cancer Research Group
Acting Chief
Dr. Terri Cornelison
301-496-8526

Prostate & Urologic Cancer Research Group
Chief
Dr. Howard Parnes
301-594-0920

Lung & Upper Aerodigestive Cancer Research Group
Chief
Dr. Eva Szabo
301-435-1595

Gastrointestinal & Other Cancer Research Group
Chief
Dr. Asad Umar
301-594-2684

Chemopreventive Agent Development Research Group
Acting Chief
Dr. Vernon Steele
301-496-8563

Community Oncology and Prevention Trials Research Group
Chief
Dr. Worta McCaskill-Stevens
301-496-8541

Nutritional Science Research Group
Acting Chief
Dr. Harold Seifried
301-594-7657

Basic Prevention Science Research Group
Acting Chief
Dr. Barnett Kramer
301-496-6616

Cancer Biomarkers Research Group
Chief
Dr. Sudhir Srivastava
301-435-1594

Early Detection Research Group
Acting Chief
Dr. Paul Pinsky
301-496-8544

Biometry Research Group
Chief
Dr. Phillip C. Prorok
301-496-8556

Cancer Prevention Fellowship Program
Director
Dr. David Nelson
301-435-5559


Division of Cancer Control and Population Sciences
Office of the Director
Director
Dr. Robert Croyle
301-594-6776
Deputy Director
Dr. Deborah Winn
301-594-9499
Senior Advisor for Cancer Surveillance
Dr. Brenda Edwards
301-496-8506
Deputy Director for Implementation Science
Dr. Russell Glasgow
301-435-4912
Office of Cancer Survivorship
Director
Dr. Julia H. Rowland
301-402-2746
Epidemiology and Genomics Research Program
Acting Associate Director
Dr. Muin Khoury
301-594-7294
Methods and Technologies Branch
Chief
Dr. Mukesh Verma
301-594-7344
Modifiable Risk Factors Branch
Chief
Dr. Britt Reid
301-435-4914
Host Susceptibility Factors Branch
Chief
Dr. Elizabeth Gillanders
301-594-5868
Clinical and Translational Epidemiology Branch
Chief
Dr. Andrew Freedman
301-435-6819
Behavioral Research Program
Associate Director
Dr. William Klein
301-435-6816
Process of Care Research Branch
Chief
Dr. Stephen Taplin
301-402-1483
Basic Biobehavioral and Psychological Sciences Branch
Chief
Dr. Paige Green McDonald
301-435-5037
Health Communication and Informatics Research Branch
Chief
Dr. Bradford Hesse
301-594-9904
Health Behaviors Research Branch
Chief
Dr. Linda Nebeling
301-435-2841
Tobacco Control Research Branch
Acting Chief
Dr. Michele Bloch
301-402-5284
Science of Research and Technology Branch
Chief
Dr. William Riley
301-435-0407
Applied Research Program
Associate Director
Dr. Rachel Ballard-Barbash
301-496-8500
Health Services and Economics Branch
Acting Chief
Dr. Steven Clausr
301-496-
Outcomes Research Branch
Chief
Dr. Steven Clauser
301-451-4402
Risk Factor Monitoring and Methods Branch
Chief
Dr. Susan Krebs-Smith
301-496-4766
Surveillance Research Program
Acting Associate Director
Dr. Eric Feuer
301-594-6776
Surveillance Systems Branch
Acting Chief
Dr. Zaria Tatalovich
301-496-8506
Data Analysis and Interpretation Branch
Chief
Dr. Kathleen Cronin
301-435-2792
Data Modeling Branch
Acting Chief
Dr. Angela Mariotto
301-435-4923
Statistical Methodology and Applications Branch
Chief
Dr. Eric Feuer
301-496-5029

Division of Cancer Treatment and Diagnosis

Office of the Director

Acting Director
Dr. Jeff Abrams
301-496-6138

Acting Director
Dr. Joseph Tomaszewski
301-496-6711

Biometrics Research Branch
Chief
Dr. Richard Simon
301-496-0975

Office of Cancer Complementary and Alternative Medicine
Associate Director
Dr. Jeffrey White
301-435-7980

Radiation Research Program
Associate Director
Dr. C. Norman Coleman
301-496-6111

Radiotherapy Development Branch
Chief
Dr. Eric Bernhard
301-435-9020

Molecular Radiation Therapeutics Branch
Chief
Dr. Stephen S. Yoo
301-496-3080

Clinical Radiation Oncology Branch
Chief
Dr. Bhadrasain Vikram
301-496-6111

Cancer Therapy Evaluation Program
Associate Director
Dr. Jeffrey Abrams
301-496-6138

Investigational Drug Branch
Chief
Dr. James Zwiebel
301-496-1196

Clinical Investigations Branch
Chief
Dr. Margaret Mooney
301-496-2522

Pharmaceutical Management Branch
Chief
Mr. Charles Hall
301-496-5725

Regulatory Affairs Branch
Chief
Dr. Jan Casadei
301-496-7912

Clinical Trials Monitoring Branch
Chief
Mr. Gary Smith
301-402-5147

Clinical Grants and Contracts Branch
Chief
Dr. Roy Wu
301-496-8866

Clinical Trials Operations and Informatics Branch
Chief
Mr. Steven Friedman
301-435-9183

Developmental Therapeutics Program
Associate Director
Dr. Jerry M. Collins
301-496-8720

Deputy Associate Director
Dr. James Crowell
301-435-9152

Information Technology Branch
Chief
Dr. Daniel Zaharevitz
301-435-9172

Biological Testing Branch
Chief
Dr. Melinda Hollingshead
301-846-5065

Biological Resources Branch
Chief
Dr. Stephen Creekmore
301-846-1100

Toxicology and Pharmacology Branch
Chief
Dr. Myrtle Davis
301-443-3404

Molecular Pharmacology Branch
Chief
Dr. Beverly Teicher
301-594-1073

Screening Technologies Branch
Acting Chief
Dr. James Crowell
301-435-9152

Natural Products Branch
Chief
Dr. David Newman
301-624-1274

Drug Synthesis and Chemistry Branch
Chief
Dr. Joel Morris
301-435-9151

Grants & Contracts Operations Branch
Chief
Dr. Mary Wolpert-DeFilippes
301-496-8783

Pharmaceutical Resources Branch
Chief
Dr. Rao Vishnuvajjala
301-496-8780

Translational Research Program
Associate Director
Dr. Toby T. Hecht
301-435-9043

Cancer Diagnosis Program
Associate Director
Dr. Barbara Conley
301-435-9004

Diagnostics Evaluation Branch
Chief
Dr. John Jessup
301-496-1591

Pathology Investigations and Resources Branch
Chief
Dr. Irina Lubensky
301-496-7147

Diagnostic Biomarkers and Technology Branch
Branch Chief
Dr. James Tricoli
301-435-9004

Biorepositories and Biospecimen Research Branch
Branch Chief
Dr. Jim Vaught
301-451-7314

Cancer Imaging Program
Associate Director
Dr. Paula Jacobs
301-435-9181

Deputy Associate Director
Vacant

Diagnostic Imaging Branch
Chief
Dr. Lalitha Shankar
301-451-8491

Molecular Imaging Branch
Acting Chief
Dr. Paula Jacobs
301-435-9181

Image-Guided Intervention Branch
Acting Chief
Dr. Laurence Clarke
301-435-9190

Imaging Technology Development Branch
Chief
Dr. Laurence Clarke
301-435-9190


Division of Extramural Activities
Office of the Director
Director
Dr. Paulette S. Gray
301-496-5147
Deputy Director
Vacant
301-496-5147
Assistant Director
Dr. Peter Wirth
301-496-7565
Office of Extramural Applications
Associate Director
Dr. Amir Sahar-Khiz
301-594-1331
Program and Review Extramural Staff Training Office
Chief
Dr. Michael Small
301-402-0996
Office of Referral, Review and Program Coordination
Associate Director
Dr. Shamala Srinivas
301-594-1224
Applied Information Systems Branch
Chief
Mr. Greg Fischetti
301-594-1067
Research Analysis and Evaluation Branch
Chief
Ms. Marilyn R. Gaston
301-594-1111
Research Programs Review Branch
Chief
Dr. Olivia T. Bartlett
301-594-2501
Program Coordination and Referral Branch
Chief
Dr. Christopher L. Hatch
301-594-1403
Resources and Training Review Branch
Chief
Dr. Robert E. Bird
301-496-7978
Special Review and Logistics Branch
Chief
Dr. Kirt J. Vener
301-496-7174

Links to Cancer Statistics

SOURCES:

Annual Report to the Nation on the Status of Cancer, 1975-2009
Annual Report to the Nation on the Status of Cancer, 1975-2009 provides information related to incidence, death rates, and trends in the United States. The report published January 2013 contains a special feature on the burden and trends in HPV-associated cancers and HPV vaccination coverage levels.
http://seer.cancer.gov/report_to_nation/

Fast Stats
Interactive tool providing tables, charts, and graphs with information related to incidence, mortality, survival and stage, prevalence, and lifetime risk (probability of developing or dying from cancer).
http://seer.cancer.gov/faststats/

SEER Cancer Statistics Review, 1975-2009
Annually updated tables and graphs displaying cancer statistics by cancer site, year of diagnosis, age, race, sex, and geography, diagnosed between 1975 and 2009. Searchable cancer statistics related to incidence, mortality, survival, prevalence, and lifetime risk.
http://seer.cancer.gov/csr/1975_2009_pops09/

Cancer Stat Fact Sheets
Collection of statistical summaries for a number of common cancer types, with information related to incidence, mortality, survival, stage, prevalence, and lifetime risk.
http://seer.cancer.gov/statfacts/

Cancer Prevalence and Cost of Care Projections
This site is based on a study that estimates and projects the national cost of cancer care through the year 2020 separately for multiple cancer sites using the most recent available U.S. population projections, cancer incidence, survival, and cost of care data.
http://costprojections.cancer.gov/index.html

REPORTS:

Costs of Cancer Care, 2010
http://progressreport.cancer.gov/doc_detail.asp?pid=1&did=2011&chid=105&coid=1026&mid=

Leading Causes of Death in the United States, 1975 and 2008
http://seer.cancer.gov/csr/1975_2008/results_merged/topic_lead_cod.pdf

Estimated New Cancer Cases and Deaths for 2011
http://seer.cancer.gov/csr/1975_2008/results_single/sect_01_table.01.pdf

Person-Years of Life Lost Due to Cancer and Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2008
http://seer.cancer.gov/csr/1975_2008/results_merged/topic_year_lost.pdf

Incidence, Mortality, and Five-Year Relative Survival Rates by Cancer Site
http://seer.cancer.gov/csr/1975_2008/results_single/sect_01_table.04_2pgs.pdf

Annual Percent Change in Incidence and Mortality Rates, 1997-2008
http://seer.cancer.gov/csr/1975_2008/results_merged/topic_graph_trends.pdf

Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity
http://seer.cancer.gov/csr/1975_2008/results_merged/topic_inc_trends.pdf

Age-Adjusted U.S. Death Rates and Trends for the Top 15 Cancer Sites by Race/Ethnicity
http://seer.cancer.gov/csr/1975_2008/results_merged/topic_mor_trends.pdf

Prevalence of Cancer: Estimated Number of Persons Diagnosed with Cancer, 5- and 32-Year Limited Duration
http://seer.cancer.gov/csr/1975_2008/results_merged/topic_prevcounts.pdf

Fiscal Year 2012 Budget

(Dollars in Thousands)

A.	**Actual Obligations Resulting From Appropriated Funds:**	
	FY 2012 Appropriation	$5,072,183
	Transfer under the HHS Secretary's transfer authority	-1,445
	Transfer for HHS Alzheimer's research initiative	-3,342
	Lapse	-54
	Actual Obligations Subtotal	**5,067,342**
B.	**Reimbursable Obligations:**	
	Reimbursements	**52,880**
C.	**Total NCI Obligations:**	**$5,120,222**

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as royalty income (see page B-7)

Program Structure Fiscal Year 2012

(Dollars in Thousands)



Budget Activity	Amount	Percent
Research:		
Cancer Causation	$1,232,813	24.3%
Detection and Diagnosis Research	451,716	8.9%
Treatment Research	1,125,431	22.2%
Cancer Biology	739,474	14.6%
Subtotal Research	**3,549,434**	**70.0%**
Resource Development:		
Cancer Centers Support	575,068	11.4%
Research Manpower Development	173,777	3.4%
Buildings and Facilities	7,920	0.2%
Subtotal Resource Development	**756,765**	**15.0%**
Cancer Prevention and Control	**311,412**	**6.1%**
Program Management and Support	**449,731**	**8.9%**
***Total NCI**	**5,067,342**	**100.0%**

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as royalty income (see page B-7)

Extramural Funds Fiscal Year 2012

(Dollars in Thousands



Mechanism	Amount	Percent
Contracts:		
R&D Contracts	589,715	15.4%
Buildings and Facilities	7,920	0.2%
Construction Contracts	0	0.0%
Subtotal Contracts	**597,635**	**15.6%**
Grants:		
Research Project Grants	2,075,295	54.1%
Cancer Centers/Specialized Centers/SPORES	612,789	16.0%
NRSA	65,992	1.7%
Other Research Grants	482,871	12.6%
Construction Grants	0	0.0%
Subtotal Grants	**3,236,947**	**84.4%**
Total Extramural Funds	3,834,582	100.0%
Total Intramural/RMS	1,232,760	
***Total NCI**	**$5,067,342**	

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as royalty income (see page B-7)

NCI Obligations by Mechanism, Fiscal Year 2012

(Dollars in Thousands)

		Number	Amount	% of Total
Research Project Grants	Non-Competing	3,746	1,639,445	32.4%
	Administrative Supplements	(184)	19,819	0.4%
	Competing	1,085	414,004	8.2%
	Subtotal, without SBIR/STTR Grants	4,831	2,073,268	40.9%
	SBIR/STTR Grants	190	77,355	1.5%
	Subtotal, Research Project Grants	**5,021**	**2,150,624**	**42.4%**
Centers & SPOREs	Cancer Centers Grants-P20/P30	67	279,877	5.5%
	SPOREs-P50	53	113,454	2.2%
	Other P50s/P20s	20	33,438	0.7%
	Other Specialized Centers	113	186,020	3.7%
	Subtotal, Centers	**253**	**612,789**	**12.1%**
Other Research	Career Program			
	Temin & Minority Mentored Awards-K01	51	6,487	0.1%
	Estab. Inv. Award-K05	23	3,453	0.1%
	Preventive Oncology-K07	76	10,941	0.2%
	Clinical Investigator-K08	105	16,479	0.3%
	Clinical Oncology-K12	18	13,398	0.3%
	Stem Cell Research-K18	1	117	0.0%
	Transitional Career Development-K22	25	4,452	0.1%
	Mentored Patient Oriented RCDA-K23	36	3,676	0.1%
	Mid-Career Invest. & Patient Orient. Res-K24	17	5,143	0.1%
	Mentored Quant. Res Career-K25	17	2,274	0.0%
	Inst. Curr. Award-K30	0	0	0.0%
	Pathway to Independence Awards-K99	53	6,744	0.1%
	Subtotal, Career Program	**422**	**73,164**	**1.4%**
	Cancer Education Program-R25	93	33,372	0.7%
	Clinical Cooperative Groups-U10	128	229,842	4.5%
	Minority Biomedical Support-S06	3	355	0.0%
	Rsch Enhance-SC1 & Pilot Research - SC2	1	340	0.0%
	Continuing Education	1	100	0.0%
	Resource Grants-R24/U24	34	64,693	1.3%
	Explor Coop Agreement-U56	0	0	0.0%
	Global Infect. Disease Rsrch Training Prog - D43	9	5,676	0.1%
	Conference Grants-R13	55	0	0.0%
	Subtotal, Other Research Grants	**746**	**407,542**	**8.0%**
Subtotal, Research Grants		**6,020**	**3,170,954**	**62.6%**
NRSA Fellowships	*Trainees:*	**1,342**	**65,992**	**1.3%**
R&D Contracts	R&D Contracts	497	552,065	10.9%
	SBIR Contracts	67	37,650	0.7%
	Subtotal, Contracts	**564**	**589,715**	**11.6%**
Intramural Research	Program		713,179	14.1%
	NIH Management Fund/SSF Assessment		144,663	2.9%
	Subtotal, Intramural Research *FTEs:*	**1,916**	**857,841**	**16.9%**
RMS	Research Mgmt and Support		333,221	6.6%
	NIH Management Fund/SSF Assessment		41,698	0.8%
	Subtotal, RMS *FTEs:*	**1,220**	**374,919**	**7.4%**
Buildings and Facilities			**7,920**	**0.2%**
Construction			**0**	**0.0%**
***Total NCI**	*FTEs:*	**3,136**	**5,067,342**	**100.0%**

*EXCLUDES projects awarded with Stamp Out Breast Cancer funds as well as royalty income (see page B-7)

Division Obligations by Mechanism, Fiscal Year 2012

(Dollars in Thousands)

CCR	DCEG	DCTD	DCB	DCCPS	DCP	DEA	OD	Research Grants	Program Support
								1,564,116	75,329
								19,819	
								414,004	
								1,997,939	75,329
								77,355	
								2,075,295	**75,329**
							279,877		
		112,810					644		
		13,084		19,785	400		168		
		6,493	32,694	13,689	2,490		130,653		
		132,387	**32,694**	**33,475**	**2,890**		**411,343**		
							6,487		
							3,453		
							10,941		
							16,479		
							13,398		
							117		
							4,452		
							3,676		
							5,143		
							2,274		
							6,744		
							73,164		
							33,372		
		140,923			87,540		1,380		
								355	
								340	
								100	
								64,693	
								5,676	
								0	
		140,923	**0**	**0**	**87,540**		**34,752**	**71,164**	
		273,309	**32,694**	**33,475**	**90,430**		**519,259**	**2,146,458**	**75,329**
							65,992		
	22,730	133,842		71,468	39,363		187,354		97,309
							37,650		
	22,730	**133,842**	**0**	**71,468**	**39,363**		**225,004**		**97,309**
417,414	67,539						193,287		34,938
									144,663
417,414	**67,539**						**193,287**		**179,601**
		47,021	10,861	28,818	16,635	20,795	174,759		34,333
									41,698
		47,021	**10,861**	**28,818**	**16,635**	**20,795**	**174,759**		**76,031**
							7,920		
417,414	**90,268**	**454,172**	**43,555**	**133,761**	**146,428**	**20,795**	**1,186,221**	**2,146,458**	**428,270**

NIH Management Fund, Service & Supply Fund, and GSA Rent
Fiscal Year 2012

(Dollars in Thousands)



DISTRIBUTION OF NCI PAYMENT	Amount	Share of NCI
Clinical Center	$113,577	61.0%
Center for Scientific Review	12,209	6.6%
Center for Information Technology	6,645	3.6%
Service and Supply Fund Assessment	18,738	10.1%
Other Research Services	14,532	7.8%
Other OD	20,658	11.1%
*Total Management Fund and SSF	186,359	100.0%
Other NIH Institutes Management Fund and SSF	1,447,716	
Total NIH Management Fund and SSF	$1,634,075	

The Management Fund provides for the financing of certain common research and administrative support activities which are required in the operations of NIH:

Clinical Center: Admissions and follow-up, anesthesiology, diagnostic x-ray, nuclear medicine, clinical pathology, blood bank, rehabilitation medicine, pharmacy, medical records, nursing services, patient nutrition services, housekeeping services, laundry, and social work.

Center for Scientific Review: Initial scientific review of applications and assignment of research grant applications to institutes.

Center for Information Technology: Research and development program in which concepts and methods of computer science are applied to biomedical problems.

GSA Rental Payments for Space: All building rental costs, including utilities and guard services.

Other Research Services: Procurement, safety, engineering, biomedical engineering, veterinary resources, and library services.

Service & Supply Fund: Mainframe computing, enterprise IT software planning and development, engineering planning and design, printing, telecommunications, procurement, shipping and receiving, motor pool, research animals, fabrication and maintenance of scientific equipment, utilities and plant maintenance, and biomedical engineering.

Special Sources of Funds

CRADAs

As a result of the Federal Technology Transfer Act of 1986 (PL 99-502), government laboratories are authorized to enter into Cooperative Research and Development Agreements (CRADAs) with private sector entities. Licensing agreements are usually incorporated into the CRADA document which addresses patent rights attributable to research supported under the CRADA.

NCI CRADA Receipts Deposited to the U.S. Treasury
(Dollars in Thousands)

Fiscal Year	Carryover from Prior Year	Collections	Obligations
2002	8,864	5,048	2,380
2003	11,533	5,221	5,361
2004	11,351	5,080	5,469
2005	10,962	6,858	4,253
2006	13,567	6,142	7,125
2007	12,584	9,410	8,360
2008	13,634	6,677	7,200
2009	13,111	5,466	4,765
2010	13,813	5,024	5,644
2011	13,150	8,582	5,894
2012	15,504	9,253	5,668

Royalty Income

NCI retains a portion of the royalty income generated by the patents related to NCI-funded research. A major portion of this royalty income is used to reward employees of the laboratory, further scientific exchange, and for education and training in accordance with the terms of the Federal Technology Transfer Act (PL 99-502). Receipts are also used to support costs associated with processing and collecting royalty income and for technology transfer efforts at NCI and NIH.

NCI Royalty Income Funding History
(Dollars in Thousands)

Years	Collections*	Inventor Payments	Other
2002/2004	42,565	3,961	38,604
2003/2005	27,271	5,262	22,009
2004/2006	26,923	4,950	21,973
2005/2007	34,086	5,745	28,341
2006/2008	29,811	6,853	22,958
2007/2009	36,344	7,210	29,134
2008/2010	50,269	8,192	42,077
2009/2011	51,621	10,225	41,396
2010/2012	58,515	5,729	52,786
**2011/2013	69,155	16,392	52,763
**2012/2014	73,060	21,640	51,420

*Does not include assessments by NIH.

**2011/2013 and 2012/2014 collections and payments are estimates.

Stamp Out Breast Cancer

The Stamp Out Breast Cancer Act (PL 105-41) was established in August 1997, extended in July 2000 (PL 106-253), November 2005 (PL 109-100), December 2007 (PL 110-150), and again in December 2011 (PL 112-80). This act allows postal customers to contribute funding to breast cancer research through their voluntary purchases of special rate postage stamps from the U.S. Postal Service. Of the funds collected above the postage costs and administrative costs, the Act requires the USPS to transfer 70% to NIH and 30% to the Department of Defense. As of September 2012, NCI has received $52,512,541. NCI has used these funds for research projects directed towards breast cancer research. Thus far, four major programs have been funded -- the "Insight Awards to Stamp Out Breast Cancer," the "Breast Cancer Research Stamp Exception Program," the "Breast Cancer Premalignancy Program" and a clinical trial to determine the risk of breast cancer recurrence. In FY 2012, $1.655 million was obligated on Breast Cancer Stamp Fund programs.

Funding for Various Research Areas

(Dollars in Millions)

The National Cancer Institute reports how appropriated funds are spent in a number of different categories or classifications including specific cancer sites, cancer types, diseases related to cancer, as well as types of research mechanisms. The table below represents funding levels for frequently requested research areas. These research areas do not represent the entire NCI research portfolio. Funding for these areas can overlap and do not add to the total NCI budget. For example, dollars for a clinical trial on breast cancer research would be included in both the Breast Cancer and the Clinical Trials lines in the table below. Similarly, a basic cancer research project may be relevant to cervical, uterine and ovarian cancers and relevant funding would be included in the figures for all three sites.

	2008 Actual	2009 Actual	2010 Actual	2011 Actual	2012 Actual
Total NCI Budget	$4,827.6	$4,966.9	$5,098.1	$5,058.1	$5,067.3
AIDS	258.5	265.9	272.1	270.0	271.7
Brain & CNS	153.7	151.5	156.8	172.6	177.5
Breast Cancer	572.6	599.5	631.2	625.1	602.7
Cervical Cancer	76.8	70.8	77.8	81.4	72.6
Clinical Trials	853.2	846.6	852.3	877.8	753.7
Colorectal Cancer	273.7	264.2	270.4	265.1	256.3
Head and Neck Cancers	76.1	77.1	62.7	61.8	71.1
Hodgkins Disease	17.5	18.2	14.6	13.4	15.6
Leukemia	216.4	220.6	239.7	227.0	234.7
Liver Cancer	74.2	70.3	72.6	66.2	64.6
Lung Cancer	247.6	246.9	281.9	296.8	314.6
Melanoma	110.8	103.7	102.3	115.6	121.2
Multiple Myeloma	41.5	45.2	48.5	54.9	61.3
Non Hodgkin's Lymphoma	122.6	130.9	122.4	126.4	119.5
Ovarian Cancer	100.0	110.1	112.3	110.8	111.7
Pancreatic Cancer	87.3	89.7	97.1	99.5	105.4
Prostate Cancer	285.4	293.9	300.5	288.3	265.1
Stomach Cancer	12.4	15.4	14.5	13.4	12.1
Uterine Cancer	17.1	18.0	14.2	15.9	19.1

Note: These figures were created using NCI's coding methodology. More information about this methodology, as well as project listings for these categories and others, are available online through NCI's Funded Research Portfolio website.

http://fundedresearch.cancer.gov/

Research Project Grants Number of Awards
Fiscal Years 2003-2012

Includes Small Business Innovation Research and Small Business Technology Transfer Awards



	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Competing	1668	1785	1428	1455	1475	1503	1388	1,387	1,106	1,220
Non-Competing	3467	3682	3984	3980	3997	3877	3791	3,692	3,913	3,801
Total	5135	5467	5412	5435	5472	5380	5179	5079	5019	5021

*EXCLUDES projects awarded with Stamp Out Breast Cancer Funds.

RPGs Requested and Awarded
Fiscal Years 2003-2012

(Dollars in Thousands)

Fiscal Year	Type		Requested		Awarded		Success
2003	Competing	New	5323	$1,675,039	1222	$347,446	
		Renewal	955	447,122	441	194,084	
		Supplement	20	4,671	5	1,338	
		Subtotal	6298	2,126,832	1668	542,868	26.5%
	Non-Competing				3467	1,457,144	
	Total				**5135**	**2,000,012**	
2004	Competing	New	6,558	$2,045,451	1,333	$339,925	
		Renewal	988	518,201	445	210,790	
		Supplement	24	8,337	7	2,196	
		Subtotal	7,570	2,571,989	1,785	552,911	23.6%
	Non-Competing				3,682	1,549,727	
	Total				**5,467**	**2,102,638**	
2005	Competing	New	6,357	$2,239,503	1,086	$309,507	
		Renewal	1,050	473,898	335	162,857	
		Supplement	22	6,147	7	1,185	
		Subtotal	7,429	2,719,548	1,428	473,549	19.2%
	Non-Competing				3,984	1,656,614	
	Total				**5,412**	**2,130,164**	
2006	Competing	New	6,585	$2,215,548	1,105	$293,912	
		Renewal	984	542,799	348	170,110	
		Supplement	13	4,098	2	681	
		Subtotal	7,582	2,762,445	1,455	464,703	19.2%
	Non-Competing				3,980	1,633,442	
	Total				**5,435**	**2,098,145**	
2007	Competing	New	6,428	$2,116,286	1,178	$306,431	
		Renewal	864	482,655	295	163,225	
		Supplement	12	3,513	2	609	
		Subtotal	7,304	2,602,454	1,475	470,265	20.2%
	Non-Competing				3,997	1,582,828	
	Total				**5,472**	**2,053,093**	
2008	Competing	New	5,944	$1,991,089	1,150	$324,070	
		Renewal	966	515,784	352	187,458	
		Supplement	1	408	1	338	
		Subtotal	6,911	2,507,281	1,503	511,866	21.7%
	Non-Competing				3,877	1,509,611	
	Total				**5,380**	**2,021,477**	
2009	Competing	New	6,167	$2,069,518	1,029	$320,980	
		Renewal	1,000	500,201	358	177,853	
		Supplement	5	1,141	1	67	
		Subtotal	7,172	2,570,860	1,388	498,900	19.4%
	Non-Competing				3,791	1,564,139	
	Total				**5,179**	**2,063,039**	
2010	Competing	New	7,494	$2,776,315	1,041	$375,830	
		Renewal	1,007	591,060	343	183,675	
		Supplement	18	6,805	3	1,491	
		Subtotal	8,519	3,374,180	1,387	560,996	16.3%
	Non-Competing				3,692	1,531,733	
	Total				**5,079**	**2,092,729**	
2011	Competing	New	8,445	$3,183,607	962	$342,196	
		Renewal	756	454,907	201	104,002	
		Supplement	29	8,871	3	460	
		Subtotal	9,230	3,647,385	1,166	446,658	12.6%
	Non-Competing				3,853	1,641,694	
	Total				**5,019**	**2,088,352**	
2012	Competing	New	8,414	$3,220,278	1,020	$351,601	
		Renewal	644	397,473	197	103,990	
		Supplement	25	9,860	3	594	
		Subtotal	9,083	3,627,611	1,220	456,185	13.4%
	Non-Competing				3,801	1,619,109	
	Total				**5,021**	**2,075,294**	

Includes Small Business Innovation Research and Small Business Technology Transfer Awards.
Success rate is the number of awarded grants divided by the number of awards requested.
Totals exclude Assessments for Program Evaluation and projects awarded with Stamp Out Breast Cancer Funds.

RPG Awards by Activity Codes

Fiscal Years 2003-2012

(Dollars in Thousands; Activity Code Descriptions on next page)

		R01	DP1	DP2	P01	R00	R37	R29	RFA	U01	U19	UH2	UM1	R03	R21	R33	R15	R55	R56	SBIR/ STTR	TOTAL
2003	#	*3,573*			*178*		*70*	*14*	*252*	*27*				*203*	*360*	*81*	*21*			*356*	*5,135*
	$	1,207,387			336,607		35,360	1,584	173,342	31,126				15,207	67,742	37,714	3,086			90,857	**2,000,012**
2004	#	*3,780*			*177*		*73*	*0*	*233*	*26*				*240*	*425*	*96*	*20*			*397*	*5,467*
	$	1,277,185			344,489		37,888	53	168,539	31,377				18,067	77,970	42,931	4,560			99,579	**2,102,638**
2005	#	*3,848*			*176*		*74*		*254*	*30*	*1*			*223*	*430*	*88*	*20*	*2*	*1*	*265*	*5,412*
	$	1,312,762			338,660		40,007		171,403	34,100	1,049			16,894	76,566	36,250	4,091	200	407	97,775	**2,130,164**
2006	#	*3,909*			*173*		*76*		*273*	*26*	*3*			*218*	*405*	*73*	*14*		*2*	*263*	*5,435*
	$	1,293,880			339,616		40,067		173,304	31,292	4,365			16,558	70,650	28,726	2,983		649	96,055	**2,098,145**
2007	#	*3,849*			*172*		*73*		*285*	*22*	*3*			*284*	*437*	*48*	*19*		*2*	*278*	*5,472*
	$	1,266,622			326,968		38,232		177,423	24,295	4,212			21,640	78,748	16,739	4,042		495	93,677	**2,053,093**
2008	#	*3,732*	*2*		*158*	*2*	*70*		*294*	*25*	*3*			*256*	*466*	*36*	*22*		*2*	*312*	*5,380*
	$	1,250,346	1,651		305,250	497	36,287		174,254	20,872	4,366			19,597	92,120	13,770	4,725		302	97,439	**2,021,476**
2009	#	*3,573*	*3*		*151*	*29*	*63*		*326*	*32*	*2*			*239*	*447*	*25*	*27*	*1*		*261*	*5,179*
	$	1,248,939	3,313		302,270	7,186	32,640		218,798	31,320	1,584			18,401	91,537	9,094	5,823	100	79	91,954	**2,063,038**
2010	#	*3,655*	*5*	*1*	*140*	*55*	*61*		*275*	*43*	*1*			*181*	*415*	*16*	*24*			*207*	*5,079*
	$	1,323,673	6,021	2,512	280,531	13,665	31,498		200,424	36,209	1,252			14,195	83,950	5,583	7,539		8	85,669	**2,092,729**
*2011	#	*3,648*	*8*		*129*	*71*	*59*		*290*	*65*	*2*	*1*		*127*	*442*	*9*	*23*			*144*	*5,019*
	$	1,331,635	7,639		259,230	17,239	30,327		194,142	47,100	5,874	255		9,646	88,481	3,166	9,183			84,054	**2,088,352**
2012	#	*3,526*	*7*	*2*	*122*	*76*	*48*		*326*	*84*	*1*	*1*	*5*	*172*	*439*	*3*	*19*			*190*	*5,021*
	$	1,318,483	7,289	4,584	243,599	18,531	23,972		204,957	53,457	1,031	100	13,467	13,132	86,384	1,182	7,772			77,355	**2,075,295**



	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
# Awarded	5,135	5,467	5,435	5,472	5,435	5,472	5,380	5,179	5,019	5,021
$ in Millions	$2,000	$2,103	$2,098	$2,053	$2,098	$2,053	$2,021	$2,063	$2,088	$2,075
Avg Cost	$389.5	$384.6	$386.0	$375.2	$386.0	$375.2	$375.7	$398.3	$416.1	$413.3

EXCLUDES projects awarded with the Stamp Out Breast Cancer Funds and Program Evaluation.

* In 2011, NCI awarded 1 UA5, it is not displayed but is included in the 2011 totals.

Activity Code Descriptions

R01	**Research Project (Traditional)** - discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specified interest and competencies.
DP1	**NIH Director's Pioneer Award (NDPA) -** Support for individuals who have the potential to make extraordinary contributions to medical research. Not renewable
DP2	**NIH Director's New Innovator Awards** support exceptionally creative new investigators who propose highly innovative projects that have the potential for unusually high impact. This award complements ongoing efforts by NIH and its institutes and centers to fund new investigators through R01 grants and other mechanisms.
P01	**Research Program Projects** - broadly based, multidisciplinary, often long-term, research program which has a specific major objective or a basic theme. A program project is directed toward a range of problems having a central research focus in contrast to the usually narrower thrust of the traditional research project.
R00	**Research Transition Award -** To support the second phase of a Career/Research Transit award program that provides 1-3 years of independent research support (R00) contingenton securing an independent research position. Award recipients will be expected to contract successfully for independent R01 support from the NIH during the R00 research transition award period.
R35	**Outstanding Investigator Grants** - long-term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential in a categorical program area.
R37	**Methods to Extend Research in Time (MERIT) Award** - long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT award during the course of review of competing research grant applications prepared and submitted in accordance with regular PHS requirements.
R29	**First Independent Research Support and Transition (FIRST) Award** - sufficient initial period of research support for newly independent biomedical investigators to develop their research capabilities and demonstrate the merit of their research ideas.
RFA	**Request for Applications** - A formal statement inviting grant or cooperative agreement applications in a well-defined scientific area to accomplish specific program purposes and indicates the amount of funds set aside for the competition and/or the estimated number of awards to be made.
U01	**Research Project Cooperative Agreement** - discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his/her specific interest and competencies.
U19	**Research Program Cooperative Agreements** - support research programs that have multiple projects directed towards specific major objective, basic theme, or program goal, requiring a broad-based, multidisciplinary, and often long-term, approach.
UH2	**Exploratory/Developmental Cooperative Agreement Phase I** - To support the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.)
UA5	**Academic Research Enhancement Award (AREA) Cooperative Agreements** - support cooperative agreements for the Academic Research Enhancement Award (AREA) program. AREA supports small scale research projects conducted by faculty in primarily baccalaureate degree-granting domestic institutions.
UM1	**Multi-Component Research Project Cooperative Agreements -** support large-scale cooperative agreements involving complex clinical trials with multiple components.
R03	**Small Grants** - research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies, which are generally for preliminary short-term projects and are non-renewable.
R15	**Academic Research Enhancement Award (AREA)** - to domestic health professional schools and other institutions offering baccalaureate or advanced degrees in health sciences, except those that have received NIH research grants and/or cooperative agreements. Supports feasibility studies and other small-scale research projects.
R21	**Exploratory/Developmental Grants** - Phase I development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R33	**Exploratory/Developmental Grants** - Phase II development of new research activities in categorical program areas. Support generally is restricted in level of support and in time.
R55	**Shannon Awards** - limited support to scientists whose research applications fall short of the cutoff for funding yet are at the "margin of excellence" whereby the perceived quality of the grant is statistically indistinguishable from grants that are funded.
R56	**High-Priority, Short-Term Project Award** - provide limited, non-renewable interim support to enable an applicant to gather additional data for revision of a new or competing renewal application.
R41	**Small Business Technology Transfer (STTR) Grants - Phase I** - limited support to projects conducted jointly by a small business concern and a research institution in which not less than 40% of the work is performed by the small business.
R42	**Small Business Technology Transfer (STTR) Grants - Phase II** - limited support to projects conducted jointly by a small business concern and a research institution in which not less than 40% of the work is performed by the small business.
R43	**Small Business Innovation Research (SBIR) Grants - Phase I** - projects limited in time and amount, to establish the technical merit and feasibility of R&D ideas which may ultimately lead to commercial products or services.
R44	**Small Business Innovation Research (SBIR) Grants - Phase II** - in-depth development of R&D ideas whose feasibility has been established in Phase I and which are likely to result in commercial products or services.

Cancer Centers by State (P30 Core Grants), Fiscal Year 2012

(Dollars in Thousands)

State	Grantee Institution	Code	Count	Amount
Alabama	University of Alabama at Birmingham	Comprehensive Core	1	$5,726
Arizona	University of Arizona	Comprehensive Core	1	3,954
California	Burnham Institute for Medical Research	Basic Core	1	3,887
	City of Hope/Beckman Research Institute	Comprehensive Core	1	2,225
	Salk Institute for Biological Studies	Basic Core	1	2,936
	Stanford University	Clinical Core	1	3,092
	University of California Davis	Clinical Core	1	3,139
	University of California Irvine	Comprehensive Core	1	1,249
	University of California Los Angeles	Comprehensive Core	1	4,576
	University of California San Diego	Comprehensive Core	1	4,282
	University of California San Francisco	Comprehensive Core	1	7,707
	University of Southern California	Comprehensive Core	1	6,532
Colorado	University of Colorado Denver	Comprehensive Core	1	3,596
Connecticut	Yale University	Comprehensive Core	1	600
Dist of Col	Georgetown University	Comprehensive Core	1	1,550
Florida	H. Lee Moffitt Cancer Center & Research Institute	Comprehensive Core	1	2,787
Georgia	Emory University	Clinical Core	1	1,493
Hawaii	University of Hawaii at Manoa	Clinical Core	1	1,150
Illinois	Northwestern University	Comprehensive Core	1	4,830
	University of Chicago	Comprehensive Core	1	4,139
Indiana	Indiana Univ-Purdue Univ at Indianapolis	Clinical Core	1	1,237
	Purdue University West Lafayette	Basic Core	1	1,195
Iowa	University of Iowa	Comprehensive Core	1	2,364
Kansas	University of Kansas Medical Center	Clinical Core	1	1,397
Maine	Jackson Laboratory	Basic Core	1	2,156
Maryland	Johns Hopkins University	Comprehensive Core	1	6,995
	University of Maryland Baltimore	Clinical Core	1	1,565
Massachusetts	Dana-Farber Cancer Institute	Comprehensive Core	1	11,165
	Massachusetts Institute of Technology	Basic Core	1	3,854
Michigan	University of Michigan at Ann Arbor	Comprehensive Core	1	5,695
	Wayne State University	Comprehensive Core	1	2,548
Minnesota	Mayo Clinic Rochester	Comprehensive Core	1	5,471
	University of Minnesota Twin Cities	Comprehensive Core	1	3,430
Missouri	Washington University	Comprehensive Core	1	4,381
Nebraska	University of Nebraska Medical Center	Clinical Core	1	1,428
New Hampshire	Dartmouth College	Comprehensive Core	1	3,126
New Jersey	Robert Wood Johnson Medical School	Comprehensive Core	1	3,002
New Mexico	University of New Mexico	Clinical Core	1	1,934
New York	Albert Einstein College of Medicine Yeshiva University	Clinical Core	1	4,257
	Cold Spring Harbor Laboratory	Basic Core	1	4,347
	Columbia University Health Sciences	Comprehensive Core	1	3,816
	New York University School of Medicine	Clinical Core	1	2,512
	Roswell Park Cancer Institute Corp	Comprehensive Core	1	3,960
	Sloan-Kettering Institute for Cancer Res	Comprehensive Core	1	13,436
North Carolina	Duke University	Comprehensive Core	1	5,724
	University of North Carolina Chapel hill	Comprehensive Core	1	7,072
	Wake Forest University Health Sciences	Comprehensive Core	1	1,393
Ohio	Case Western Reserve University	Comprehensive Core	1	4,849
	Ohio State University	Clinical Core	1	4,582
Oregon	Oregon Health and Science University	Clinical Core	1	1,135
Pennsylvania	Fox Chase Cancer Center	Comprehensive Core	1	4,062
	Thomas Jefferson University	Clinical Core	1	2,947
	University of Pennsylvania	Comprehensive Core	1	7,725
	University of Pittsburgh at Pittsburgh	Comprehensive Core	1	5,340
	Wistar Institute	Basic Core	1	2,517
South Carolina	Medical University of South Carolina	Clinical Core	1	1,401
Tennessee	St. Jude Children's Research Hospital	Comprehensive Core	1	5,675
	Vanderbilt University	Comprehensive Core	1	5,899
Texas	Baylor College of Medicine	Clinical Core	1	2,935
	University of Texas M.D. Anderson Cancer Center	Comprehensive Core	1	9,988
	University of Texas San Antonio Health Science Center	Clinical Core	1	1,300
	University of Texas Southwestern Medical Center	Clinical Core	1	1,425
Utah	University of Utah	Clinical Core	1	1,455
Virginia	University of Virginia Charlottesville	Clinical Core	1	2,383
	Virginia Commonwealth University	Clinical Core	1	1,423
Washington	Fred Hutchinson Cancer Research Center	Comprehensive Core	1	11,585
Wisconsin	University of Wisconsin Madison	Comprehensive Core	1	4,556
	Total P30s		**67**	**262,089**
	Planning Grants (P20s)		16	2,992
	Other P20, P30 & U41		0	9,826
	Total Cancer Centers		**67**	**274,908**

Specialized Programs of Research Excellence, Fiscal Year 2012

(Dollars in Thousands)

In 1992, the NCI established the Specialized Programs of Research Excellence (SPORE). The Translational Research Program (TRP) is the home of the SPOREs — a cornerstone of NCI's efforts to promote collaborative, interdisciplinary translational cancer research. SPORE grants involve both basic and clinical/applied scientists, and support projects that will result in new and diverse approaches to the prevention, early detection, diagnosis and treatment of human cancers.

Each SPORE is focused on a specific organ site, such as breast or lung cancer, or on a group of highly related cancers, such as gastrointestinal cancers. SPOREs are designed to enable the rapid and efficient movement of basic scientific findings into clinical settings, as well as to determine the biological basis for observations made in individuals with cancer or in populations at risk for cancer. For more information, see http://trp.cancer.gov.

Mechanism	Site	No.	Amount
P50 SPOREs	Brain	3	$4,761
	Breast	6	13,495
	Cervical	1	2,390
	Genitourinary	2	4,332
	Gastrointestinal	5	9,790
	Head and Neck	3	5,944
	Leukemia	2	4,594
	Lung	6	13,586
	Lymphoma	4	9,300
	Myeloma	2	4,600
	Ovarian	4	9,123
	Pancreatic	3	5,667
	Prostate	6	11,397
	Skin	5	11,473
	Uterine	1	2,300
	Subtotal	53	112,753
P20	Brain	1	700
	Total P20	1	700
Co-funded	Head & Neck with NIDCR		1
	Total Co-funded		1
Total NCI SPOREs and NCI SPORE Funding		**54**	**$113,454**

NRSA Predoctoral and Postdoctoral Trainees
Fiscal Years 2000-2012

(Full Time Trainee Positions)



	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Predoc	605	582	546	499	492	511	503	476	464	497
Postdoc	915	897	923	934	963	1,003	989	952	911	845
Total	1,520	1,479	1,469	1,433	1,455	1,514	1,492	1,428	1,375	1,342

Construction/Renovation Funding and Building & Facilities Funding Fiscal Years 2001 - 2012

(Dollars in Thousands)

Construction/Renovation grants and contracts were used by grantees to build infrastructure. The grants (C06s) provide matching Federal funds for up to 50% of allowable costs for construction or major remodeling to create new facilities for cancer research. Although the NCI has the authority to fund Construction grants, Congress has not appropriated funds to this program for NCI since FY 2003. In FY 2005, NCI began to recieve Building & Facilities funding to use specifically for repairs and improvements at the NCI - Frederick facility.



Grant and Contract Awards by State Fiscal Year 2012

(Dollars in Thousands)

State	Grants		Contracts		Total	
	No	Amount	No	Amount	No	Amount
Alabama	59	$31,164	5	$2,709	64	$33,873
Arizona	59	31,816	1	187	60	32,003
Arkansas	18	8,466	2	2,200	20	10,666
California	835	418,849	41	31,475	876	450,324
Colorado	87	30,476			87	30,476
Connecticut	94	34,190	1	2,137	95	36,327
Delaware	3	1,966	1	200	4	2,166
District of Columbia	62	25,322	10	3,068	72	28,390
Florida	180	71,100	7	2,575	187	73,675
Georgia	98	31,939	10	5,789	108	37,728
Hawaii	24	19,638	2	1,364	26	21,002
Idaho					0	0
Illinois	242	106,315	15	4,505	257	110,820
Indiana	69	22,604			69	22,604
Iowa	39	16,021	1	4,818	40	20,839
Kansas	31	12,047			31	12,047
Kentucky	51	13,346	1	1,361	52	14,707
Louisiana	41	10,639	1	1,705	42	12,345
Maine	7	4,977			7	4,977
Maryland	237	124,846	59	430,590	296	555,436
Massachusetts	615	352,524	14	7,811	629	360,335
Michigan	223	110,636	2	7,223	225	117,859
Minnesota	187	103,156	6	2,575	193	105,731
Mississippi	5	1,414			5	1,414
Missouri	98	55,772	7	5,323	105	61,095
Montana	1	413	1	1,500	2	1,912
Nebraska	45	21,411			45	21,411
Nevada	3	1,189			3	1,189
New Hampshire	37	19,702	2	275	39	19,977
New Jersey	88	29,446	6	6,116	94	35,562
New Mexico	24	12,419	1	2,319	25	14,738
New York	587	287,390	10	5,517	597	292,907
North Carolina	286	126,184	11	3,046	297	129,230
North Dakota	2	564			2	564
Ohio	214	96,970	7	5,216	221	102,186
Oklahoma	9	2,970	2	3,302	11	6,272
Oregon	48	20,934			48	20,934
Pennsylvania	467	242,116	4	2,016	471	244,133
Rhode Island	30	8,278	2	230	32	8,508
South Carolina	50	18,012			50	18,012
South Dakota	8	3,158			8	3,158
Tennessee	191	98,735	2	1,695	193	100,430
Texas	489	239,155	8	4,631	497	243,786
Utah	56	24,691	2	2,013	58	26,704
Vermont	6	4,904			6	4,904
Virginia	96	54,633	9	4,141	105	58,774
Washington	206	134,766	10	15,759	216	150,525
West Virginia	9	2,352			9	2,352
Wisconsin	99	45,513	1	303	100	45,816
Wyoming	1	182			1	182
Subtotal	**6,416**	**3,135,310**	**264**	**575,692**	**6,680**	**3,711,003**
Guam	1	1,320			1	1,320
Puerto Rico	8	4,702			8	4,702
Total	**6,425**	**3,141,333**	**264**	**575,692**	**6,689**	**3,717,025**

Excludes STAMP, NRSA TAP, Loan Repayment Program, Foreign Contracts and Grants, Program Evaluation, and other assessments and miscellaneous expenses.

Grant and Contract Awards by Country
Fiscal Year 2012

(Dollars in Thousands)

Country	Grant		Contract		Total	
	No	Amount	No	Amount	No	Amount
Argentina	0	$75			0	$75
Australia	4	904			4	904
Belgium	1	235			1	235
Canada	19	9,037	2	$1,543	21	10,580
Costa Rica			2	2,866	2	2,866
France	6	4,125			6	4,125
India	1	196			1	196
Ireland	1	184			1	184
Israel	5	1,200			5	1,200
Korea	1	171			1	171
Malawi	0	150			0	150
Netherlands	1	217	1	90	2	307
Spain	1	224			1	224
Switzerland	1	624			1	624
United Kingdom	6	1,208	2	43	8	1,251
Total Foreign	**47**	**18,552**	**7**	**4,542**	**54**	**23,019**

Excludes STAMP, NRSA TAP, Loan Repayment Program, Program Evaluation, and other assessments and miscellaneous expenses.

Institutions Receiving More than $15 Million in NCI Support, FY 2012

(Dollars in Thousands)

State	Institution	Grants	Contracts	Total NCI
Alabama	University of Alabama at Birmingham	$25,402	$2,225	$27,627
Arizona	University of Arizona	20,590	187	20,777
California	Burnham Institute for Medical Research	20,030		20,030
	City of Hope's Beckman Research Institute	25,524		25,524
	Stanford University	44,303		44,303
	University of California System	158,382	2,479	160,861
	University of Southern California	38,968	2,486	41,454
Colorado	University of Colorado Health Sciences Center	22,114		22,114
Connecticut	Yale University	28,235		28,235
District of Columbia	Georgetown University	19,221	1,504	20,725
Florida	H. Lee Moffitt Cancer Center & Research Institute	35,013	735	35,748
Georgia	Emory University	20,223	2,437	22,660
Hawaii	University of Hawaii at Manoa	17,898	1,364	19,262
Illinois	Northwestern University	30,179	382	30,561
	University of Chicago	29,183	1,433	30,616
	University of Illinois at Chicago	19,706	247	19,953
Iowa	University of Iowa	13,973	4,818	18,791
Maryland	The Johns Hopkins University	79,738	4,857	84,595
	SAIC-Frederick, Inc.		238,204	238,204
	Westat, Inc.		23,697	23,697
	Gynecologic Oncology Group	18,470		18,470
Massachusetts	Beth Israel Deaconess Medical Center	19,784		19,784
	Brigham and Women's Hospital	52,563	25	52,588
	Broad Institute, Inc.	24,233		24,233
	Dana-Farber Cancer Institute	74,463		74,463
	Harvard University	21,122		21,122
	Massachusetts General Hospital	45,618	15	45,633
	Massachusetts Institute of Technology	23,314		23,314
	University of Massachusetts Medical School Worcester	13,351		13,351
Michigan	University of Michigan at Ann Arbor	73,576		73,576
	Wayne State University	17,438	4,784	22,222
Minnesota	Mayo Clinic in Rochester	64,128	1,015	65,143
	University of Minnesota	33,956	171	34,127
Missouri	Washington University	50,552	268	50,820
Nebraska	University of Nebraska Medical Center	18,024		18,024
New Hampshire	Dartmouth College	19,211	25	19,236
New York	Columbia University Health Sciences	34,228		34,228
	Mount Sinai School of Medicine	24,137		24,137
	New York University	18,742		18,742
	Roswell Park Cancer Institute Corporation	29,312		29,312
	Sloan-Kettering Institute for Cancer Research	69,849	1,670	71,519
	University of Rochester	15,878		15,878
	Yeshiva University	24,997		24,997
North Carolina	Duke University	39,015	25	39,040
	University of North Carolina at Chapel Hill	59,385		59,385
Ohio	Case Western Reserve University	21,486		21,486
	Ohio State University	45,474	1,121	46,595
Pennsylvania	University of Pennsylvania	60,712		60,712
	University of Pittsburgh	51,958	449	52,407
	Wistar Institute	15,005		15,005
Tennessee	St. Jude Children's Research Hospital	24,170		24,170
	Vanderbilt University	65,841		65,841
Texas	Baylor College of Medicine	41,624		41,624
	University of Texas, MD Anderson Cancer Center	117,206	1,739	118,945
	University of Texas, SW Medical Center at Dallas	18,166		18,166
Utah	University of Utah	22,002	1,813	23,815
Virginia	American College of Radiology	21,949		21,949
	University of Virginia at Charlottesville	16,096		16,096
Washington	Fred Hutchinson Cancer Research Center	82,478	3,653	86,131
	University of Washington	34,269		34,269
Wisconsin	University of Wisconsin	30,281	303	30,584
	Total	$2,202,742	$304,131	$2,506,873

Includes Manpower Development Grants

Appropriations of the NCI 1938-2012

(In Whole Dollars)

1938 - 2001	**$48,750,577,220**	
2002.....	4,190,405,000	*prior to reductions in PL 107-116(-$4,524,000 via the Secretary's 1% transfer authority, -$2,054,000 for the enacted rescission, -$7,118,000 administrative reduction and -$8,000 lapse). Includes $254,396,000 of AIDS funding.*
2003.....	4,622,394,000	*prior to reductions in PL 108-7(-$30,046,000 for the enacted rescission and -$2,000 lapse). Includes $263,442,000 of AIDS funding.*
2004.....	4,770,519,000	*prior to reductions in PL 108-199(-$3,136,000 for Labor/HHS/ED rescission; $28,128,000 for across the board reduction; -$15,357,000 NIH 1% transfer assessment, and $5,000 lapse). Includes $266,975,000 of AIDS funding.*
2005.....	4,865,525,000	*prior to reductions in PL 108-447($38,914,000 .8% across the board reduction; -$1,353,000 for Labor/HHS/ED rescission; -$30,505,000 NIH 1% transfer assessment, and $9,000 lapse). Includes $265,907,000 of AIDS funding.*
2006.....	4,841,774,000	*prior to reductions in PL 109-149 (-$48,418,000 for Labor/HHS/ED rescission; -$3,293,000 HHS transfer for CMS activities; -$42,834,000 NIH 1% transfer for roadmap activities, and $4,000 lapse). Includes $253,866,000 of AIDS funding.*
2007.....	4,797,639,000	*prior to reductions in PL 110-5 (-$5,015,000 NIH transfer for GEI activities, and $9,000 lapse). Includes $253,866,000 of AIDS funding.*
2008……	4,827,556,000	*Includes supplemental appropriation of $25,559,000. Includes $258,499,000 of AIDS funding.*
2009……	4,968,973,000	*prior to reductions in PL 111-8 (-$2,042,631 NIH transfer for activities, and $4000 lapse). Includes $265,882,000 of AIDS funding.*
2010……	5,103,388,000	*prior to -$760,000 HHS Secretary's transfer ,-$4,459,000 in NIH transfer for activities, and $22,000 lapse. Includes $272,130,000 of AIDS funding.*
2011……	5,058,577,000	*prior to $472,000 lapse. Includes $269,953,000 of AIDS funding.*
2012……	5,072,183,000	*prior to -$1,445,000 HHS Secretary's transfer ,-$3,342,000 HHS Secretary's transfer for Alzheimer's research, and $54,000 lapse.Includes $271,692,000 of AIDS funding.*
1938-2011	**101,869,510,220**	

Bypass Budget Requests
Fiscal Years 1974-2012

(in Whole Dollars)

Fiscal Year	Request
1974	640,031,000
1975	750,000,000
1976	898,500,000
1977	948,000,000
1978	955,000,000
1979	1,036,000,000
1980	1,055,000,000
1981	1,170,000,000
1982	1,192,000,000
1983	1,197,000,000
1984	1,074,000,000
1985	1,189,000,000
1986	1,460,000,000
1987	1,570,000,000
1988	1,700,000,000
1989	2,080,000,000
1990	2,195,000,000
1991	2,410,000,000
1992	2,612,000,000
1993	2,775,000,000
1994	3,200,000,000
1995	3,600,000,000
1996	3,640,000,000
1997	2,977,000,000
1998	2,702,500,000
1999	3,191,000,000
2000	3,873,000,000
2001	4,135,000,000
2002	5,030,000,000
2003	5,690,000,000
2004	5,986,000,000
2005	6,211,000,000
2006	6,170,000,000
2007	5,949,714,000
2008	5,865,788,000
2009	6,028,386,000
2010	7,193,393,000
2011	6,199,666,000
2012	5,869,857,000
2013	5,833,010,000
2014	To be determined*

The National Cancer Act in December 1971 included a provision for the Director, NCI, to submit an annual budget request directly to the President, with comment only by NIH and DHHS. This Bypass Budget was first submitted for 1973.

*As of publication, the FY 2014 figures were still under development. When figures are finalized they will be available online at www.cancer.gov

Bypass Requests and Appropriations of the NCI
Fiscal Years 1974-2013



*As of publication, the FY 2014 figures were still under development. When figures are finalized they will be available online at www.cancer.gov

Comparison of Dollars, Positions, and Space
Fiscal Years 2003-2012

Funds are obligations against the annual appropriation in millions of dollars.
FTEs are the number of workyears for appointed employees of the NCI. A workyear equals 2,080 hours.
Space is in thousands of square feet, excluding NCI-Frederick.



	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Funds	$4,592	$4,724	$4,795	$4,747	$4,793	$4,828	$4,967	$5,098	$5,058	$5,067
FTEs	3,166	3,108	2,854	2,777	2,828	2,882	2,956	3,056	3,135	3,136
Space (Sq Ft)	835	867	937	969	934	916	955	983	952	952



	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Funds	10%	3%	1%	-1%	1%	1%	3%	3%	-1%	0.2%
FTEs	2%	-2%	-8%	-3%	2%	2%	3%	3%	3%	0%
Space (Sq Ft)	0%	4%	8%	3%	-4%	-2%	4%	3%	-3%	0%

Personnel Resources
Fiscal Years 2002-2012

Fiscal Year	Full Time Permanent Appointment	Full Time Permanent Appointment	Training Fellows	Total Personnel Resources
2002	2,250	979	949	4,178
2003	2,193	1,073	1,191	4,457
2004	2,083	990	1,232	4,305
2005	1,959	882	1,077	3,918
2006	2,579	289	1,113	3,981
2007	2,421	498	1,111	4,030
2008	2,075	920	1,016	4,011
2009	2,118	959	1,058	4,135
2010	2,148	1,011	1,073	4,232
2011	2,180	1,029	1,108	4,317
2012	2,139	997	906	4,042

AIDS Funding History
Fiscal Years 1996 - 2012

Fiscal Year	NCI	NIH	% NCI of NIH
1996	225,360	1,411,860	16%
1997	224,733	1,501,073	15%
1998	225,991	1,559,071	14%
1999	239,190	1,797,422	13%
2000	244,145	2,005,100	12%
2001	237,789	2,244,160	11%
2002	254,396	2,500,866	10%
2003	263,442	2,718,171	10%
2004	266,975	2,840,384	9%
2005	265,907	2,909,381	9%
2006	253,666	2,902,183	9%
2007	253,666	2,904,536	9%
2008	258,499	2,928,300	9%
2009	265,882	3,019,279	9%
2010	272,130	3,085,597	9%
2011	269,953	3,059,243	9%
2012	271,692	3,076,056	9%



NIH Publication No. 13-7874
Printed July 2013

NIH...Turning Discovery Into Health®